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SCIENTIFIC OPINION 
Scientific Opinion on application EFSA-GMO-NL-2007-45 for the placing 
on the market of herbicide-tolerant, high-oleic acid, genetically modified 
soybean 305423 for food and feed uses, import and processing under 
Regulation (EC) No 1829/2003 from Pioneer
1 
EFSA Panel on Genetically Modified Organisms (GMO)
2,3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Soybean 305423 was developed through particle bombardment and contains gm-fad2-1 and gm-hra expression 
cassettes, conferring a high oleic acid profile and tolerance to acetolactate synthase (ALS)-inhibiting herbicides. 
Bioinformatic analyses and genetic stability studies did not raise safety issues. Levels of the GM-HRA protein in 
soybean 305423 have been sufficiently analysed. Soybean 305423 differs from the conventional counterpart in 
the seed fatty acid profile and for the presence of the GM-HRA protein. It is agronomically equivalent to non-
GM reference soybeans. The safety assessment of GM-HRA identified no concerns regarding potential toxicity 
and  allergenicity.  There  are  no  indications  that  the  overall  allergenicity  of  soybean 305423  has  changed. 
Nutritional assessment on soybean 305423 oil and derived food products did not identify concerns on human 
health and nutrition. There are no concerns regarding the use of feeding stuffs derived from soybean 305423. 
There are no indications of an increased likelihood of establishment and spread of feral GM soybean plants. 
Environmental  risks  associated  with  an  unlikely,  but  theoretically  possible,  horizontal  gene  transfer  from 
soybean 305423 to bacteria have not been identified. Potential biotic and abiotic interactions of soybean 305423 
were  not  considered  to  be  an  issue  owing  to  the  low  level  of  environmental  exposure.  The  post-market 
environmental monitoring plan is in line with the scope of soybean 305423. The EFSA GMO Panel considers 
that the information available for  soybean 305423 addresses the scientific comments  raised by  the Member 
States  and  states  that  the  soybean 305423,  as  described  in  the  application,  is  as  safe  as  its  conventional 
counterpart with respect to potential effects on human and animal health and the environment in the context of 
the  scope.  The  GMO  Panel  recommends  a  post-market  monitoring  plan,  focusing  on  the  collection  of 
consumption data for the European population, for the marketed foods and feed.  
© European Food Safety Authority, 2013 
 
                                                       
1  On request from the Competent Authority of the Netherlands for an application EFSA-GMO-NL-2007-45 submitted by 
Pioneer, Question No EFSA-Q-2007-122, adopted on 4 December 2013. 
2  Panel  members:  Salvatore  Arpaia,  Andrew  Nicholas  Edmund  Birch,  Andrew  Chesson,  Patrick  du  Jardin,  Achim 
Gathmann, Jürgen Gropp, Lieve Herman, Hilde-Gunn Hoen-Sorteberg, Huw Jones, József Kiss, Gijs Kleter, Martinus 
Løvik, Antoine Messéan, Hanspeter Naegeli, Kaare Magne Nielsen, Jaroslava Ovesn á, Joe Perry, Nils Rostoks   and 
Christoph Tebbe. Correspondence: gmo@efsa.europa.eu  
3  Acknowledgement:  The  Panel  wishes  to  thank  the  members  of  the  Standing  Working  Groups  on  Molecular 
Characterisation, Food and Feed Risk Assessment and Environmental Risk Assessment: Thomas Frenzel, Annette Pöting 
and Hildegard Przyrembel for the preparatory  work on  this scientific opinion, and the  EFSA staff members: Hermann 
Broll, Anna Christodoulidou, Zoltán Divéki, Anna Lanzoni, Yi Liu, Karine Lheureux and Sylvie Mestdagh for the support 
provided to this scientific opinion. Scientific opinion on GM soybean 305423 
 
EFSA Journal 2013;11(12):3499  2 
KEY WORDS 
GMO, soybean (Glycine max), herbicide tolerant, high oleic acid, RNAi, HRA, Regulation (EC) No 1829/2003 
   Scientific opinion on GM soybean 305423 
 
EFSA Journal 2013;11(12):3499  3 
SUMMARY 
Following  the  submission  of  an  application  (EFSA-GMO-NL-2007-45)  under  Regulation  (EC) 
No 1829/2003 from Pioneer, the Panel on Genetically Modified Organisms of the European Food 
Safety  Authority  (EFSA  GMO  Panel)  was  asked  to  deliver  a  scientific  opinion  on  the  safety  of 
herbicide-tolerant, high-oleic acid genetically modified (GM) soybean 305423 (Unique Identifier DP-
3Ø5423-1) for food and feed uses, import and processing. 
In delivering its scientific opinion, the EFSA GMO Panel considered the application EFSA-GMO-NL-
2007-45,  additional  information  supplied  by  the  applicant,  scientific  comments  submitted  by  the 
Member States and relevant scientific publications. The scope of application EFSA-GMO-NL-2007-
45 is for food and feed uses, import and processing of soybean 305423 within the European Union 
(EU) as any non-GM soybean, but excludes cultivation in the EU. 
The  EFSA  GMO  Panel  evaluated  soybean 305423  with  respect  to  the  scope  and  the  appropriate 
principles described in its Guidance documents for the risk assessment of GM plants and derived food 
and feed and on the post-market environmental monitoring of GM plants (EFSA, 2006a, 2011a).The 
scientific assessment included molecular characterisation of the inserted DNA, the expression of the 
target  protein  and  the  high-oleic  acid  phenotype.  An  evaluation  of  the  comparative  analysis  of 
composition  and  agronomic  and  phenotypic  traits  was  undertaken,  and  the  safety  of  the  newly 
expressed  proteins  and  the  whole  food/feed  was  evaluated  with  respect  to  potential  toxicity, 
allergenicity and nutritional quality. An evaluation of environmental impacts and of the post-market 
environmental monitoring plan was undertaken. 
Soybean 305423 was transformed using a biolistic DNA delivery system and expresses the Glycine 
max-hra  (gm-hra)  gene  conferring  tolerance  to  acetolactate  synthase  (ALS)-inhibiting  herbicides. 
Soybean 305423 also expresses a fragment of the endogenous fad2-1 gene resulting, through RNA 
interference, in the silencing of the endogenous fad2-1 gene, which leads to a decreased level of the 
omega-6 fatty acid desaturase and a high-oleic acid phenotype. 
The  molecular  characterisation  data  establish  that  the  genetically  modified  (GM)  soybean 305423 
contains  four  complete  and/or  partial  copies  of  the  Glycine  max-fad2-1  (gm-fad2-1)  and  gm-hra 
expression  cassettes.  No  other  parts  of  the  plasmid  used  for  transformation  are  present  in  the 
transformed plant except for a small, non-functional vector fragment which does not include the origin 
of replication or the hygromycin-resistance gene. Results of updated bioinformatic analyses of the 5′ 
and 3′ flanking sequences and open reading frames (ORFs) present in the junction regions and within 
the  insert  did  not  indicate  a  safety  issue.  One  plant  among  the  1 100  tested  had  undergone 
recombination  and,  as  a  result,  had  lost  the  entire  gm-hra  cassette  and  portions  of  the  promoter 
elements  flanking  the  cassette.  However,  the  EFSA  GMO  Panel  is  of  the  opinion  that  this 
recombination, leading to loss of the trait, raises no safety issue. The stability of the inserted DNA was 
sufficiently confirmed over several generations. The four insertions are genetically linked and behave 
as a single Mendelian locus. 
The EFSA GMO Panel compared the compositional, agronomic and phenotypic characteristics of 
soybean 305423,  with  its  conventional  counterpart  and  non-GM  reference  soybean  varieties  and 
assessed  all  statistically  significant  differences  between  soybean 305423  and  its  conventional 
counterpart, for which equivalence with the non-GM reference varieties could not be established. The 
EFSA  GMO  Panel  concludes  that  the  composition  of  soybean 305423  differs  from  that  of  the 
conventional counterpart and that of non-GM reference varieties in its fatty acid profile, the newly 
expressed  protein  max  herbicide-resistant  ALS  (GM-HRA),  consistently  with the  objective  of  the 
modification as well as with the expression of the ALS enzyme of soybean 305423; differences in the 
minerals  zinc  and  calcium  and  the  isoflavone  glycitin  were  also  noted,  and  for  these  no  further 
assessment was deemed necessary owing to their well-known biochemical roles and to the magnitude 
of the reported levels. The EFSA GMO Panel also concludes that no differences were identified in the 
agronomic and phenotypic characteristics that would require further assessment with regard to safety. Scientific opinion on GM soybean 305423 
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Full  replacement  of  vegetable  oils  with  oil  derived  from  soybean 305423  would  not  change 
substantially the average intake of  saturated fatty acids (SFA) and n-3 polyunsaturated fatty acids 
(PUFA), but would increase average intake of monounsaturated fatty acids (MUFA) and odd chain 
fatty acids, and decrease n-6 PUFA intake. These changes in the average intake are small and without 
impact on health and nutrition. The contribution of fatty acids from soybean 305423 in other soybean 
products to overall human exposure would be small and is not expected to affect the conclusion on 
human health and nutrition. 
The safety assessment identified no concerns regarding the potential toxicity and allergenicity of the 
newly introduced GM-HRA protein. There are no indications that the genetic modification might 
significantly  change  the  overall  allergenicity  of  soybean 305423  when  compared  with  that  of  its 
conventional counterpart. 
Based on the results of studies in chickens for fattening, laying hens, pigs and rats, it is concluded that 
feeding stuffs derived from soybean 305423 are safe and as nutritious as those derived from other non-
GM soybean varieties for all animal species. 
Considering the intended altered soybean 305423 nutritional composition, a proposal for a post-market 
monitoring  (PMM)  plan  needs  to  be  provided  by  the  applicant  (EFSA,  2006b ,  2011c).  EFSA 
recommends that the PMM  should focus on the collection of consumption data for the European 
population. 
The scope of application EFSA-GMO-NL-2007-45 is for food and feed uses, import and processing 
and does not include cultivation. Therefore, there is no requirement for scientific information on 
possible environmental effects associated with the cultivation of soybean 305423 in Europe. There are 
no indications of an increased likelihood of establishment and spread of feral GM soybean plants in 
the case of accidental release into the environment of viable soybean 305423 grains during transport 
and  processing  for  food  and  feed  uses,  except  in  the  presence  of  ALS -inhibiting  herbicides. 
Considering the scope of this application, potential biotic and abiotic interactions of soybean 305423 
were not considered to be an issue by the EFSA GMO Panel. The unlikely but theoretically possible 
transfer of the recombinant gene from soybean 305423 to environmental bacteria does not raise safety 
concerns because no selective advantage will be conferred to the recipients. The scope of the post-
market environmental monitoring plan provided by the applicant is in line with the  scope of the 
application. Furthermore, the EFSA GMO Panel agrees with the reporting intervals proposed by the 
applicant in the post-market environmental monitoring plan. 
In conclusion, the EFSA GMO Panel considers that the information available for  soybean 305423 
addresses the scientific issues indicated by the Guidance document of the EFSA GMO Panel and the 
scientific  comments  raised  by  the  Member  States,  and  that  soybean 305423  is  as  safe  as  its 
conventional counterpart and is unlikely to have adverse effects on human and animal health and the 
environment in the context of the scope of this application. 
Considering the altered composition and nutritional values of soybean 305423, the EFSA GMO Panel 
considered a specific labelling proposal provided by the applicant in accordance with Articles 13(2)(a) 
and 25(2)(c) of Regulation (EC) No 1829/2003. The applicant proposed that food and feed products 
within the scope of the application should be labelled as ―genetically modified soybean with altered 
fatty acid profile‖. The GMO Panel is of the opinion that the compositional data show that the fatty 
acid composition of seeds of soybean 305423 and derived oil has indeed been changed in relation to 
the conventional counterpart. Scientific opinion on GM soybean 305423 
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BACKGROUND 
On 18 June 2007, the European Food Safety Authority received from the Dutch Competent Authority 
an application (Reference EFSA-GMO-NL-2007-45) for authorisation of genetically modified (GM) 
soybean 305423 (Unique Identifier  DP-3Ø5423-1) submitted by Pioneer within the framework of 
Regulation (EC) No 1829/2003 on GM food and feed.
4 After receiving the application EFSA-GMO-
NL-2007-45 and in accordance with Articles 5(2)(b) and 17(2)b of Regulation (EC) No 1829/2003, 
EFSA informed the Member Stat es and the European Commission, and made the summary of the 
application publicly available on the EFSA website. EFSA initiated a formal review of the application 
to check compliance with the requirements laid down in Articles 5(3) and 17(3) of Regulation ( EC) 
No 1829/2003. On 22 October 2007, EFSA declared the application as valid in accordance with 
Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003. 
EFSA made the valid application available to Member States and the European Commission and 
consulted nominated risk assessment bodies of the Member States, including the national Competent 
Authorities within the meaning of Directive 2001/18/EC
5, following the requirements of Articles 6(4) 
and 18(4) of Regulation (EC) No 1829/2003, to request their scientifi c opinion. Member States had 
three months after the date of receipt of the valid application (until 22 January 2008) within which to 
make their opinion known. 
The EFSA GMO Panel carried out a scientific assessment of genetically modified (GM) soybean 
305423 in accordance with Articles 6(6) and 18(6) of Regulation (EC) No 1829/2003, taking into 
account the appropriate principles described in the guidance documents of the Scientific Panel on 
Genetically Modified Organisms for the risk assessment of food and f eed derived from genetically 
modified plants (EFSA, 2006a, 2011a). In addition, the scientific comments of Member States, the 
additional information provided by the applicant and relevant scientific publications were taken into 
consideration. 
On 20 December 2007, 28 February 2008, 22 May 2008, 13 August 2008, 11 February 2009, 
8 January 2010, 27 April 2010, 5 August 2010, 21 October 2010, 30 May 2012, 19 September 2012, 8 
February 2013, 20 February 2013, 12 April 2013 and 26 June 2013 the EFSA GMO Panel req uested 
additional  information  from  the  applicant.  The  applicant  provided  additional  information  on 
12 February 2008, 28 April 2008, 4 July 2008, 24 November 2008, 19 March 2009, 6 October 2009, 
9 February 2010,  9 June 2010,  21 September 2010,  9 February 2011,  14 July 2011,  28  November 
2011, 17 January 2012, 5 March 2012, 5 June 2012, 31 October 2012, 2 May 2013, 28 June 2013 and 
on 3 October 2013. After receipt and assessment of the full data package, the GMO Panel finalised its 
risk assessment of soybean 305423. 
In giving its opinion on soybean 305423 to the European Commission, the Member States and the 
applicant, and in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003, EFSA 
has endeavoured to respect a time limit of six months from  the acknowledgement of the valid 
application. As additional information was requested by the EFSA GMO Panel, the time -limit of 6 
months was extended accordingly, in line with Articles 6(1), 6(2), 18(1), and 18(2) of Regulation (EC) 
No 1829/2003. 
According  to Regulation (EC) No 1829/2003, this scientific opinion is to be seen as the report 
requested under Articles 6(6) and 18(6) of that Regulation and thus will be part of the EFSA overall 
opinion in accordance with Articles 6(5) and 18(5). 
                                                       
4  Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically 
modified food and feed. Official Journal of the European Communities, L 268, 1–23. 
5 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the 
environment  of  genetically  modified  organisms  and  repealing  Council  Directive  90/220/EEC.  Official  Journal  of  the 
European Communities, L 106, 1–38. Scientific opinion on GM soybean 305423 
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TERMS OF REFERENCE 
The EFSA GMO Panel was requested to carry out a scientific assessment of soybean 305423 (Unique 
Identifier DP-305423-1) for food and feed uses, import and processing in accordance with Articles 
6(6) and 18(6) of Regulation (EC) No 1829/2003. 
Where  applicable,  any  conditions  or  restrictions  which  should  be  imposed  on  the  placing  on  the 
market  and/or  specific  conditions  or  restrictions  for  use  and  handling,  including  post-market 
monitoring requirements based on the outcome of the risk assessment and, in the case of GMOs or 
food/feed  containing  or  consisting  of  GMOs,  conditions  for  the  protection  of  particular 
ecosystems/environment and/or geographical areas should be indicated in accordance with Articles 
6(5)(e) and 18(5)e of Regulation (EC) No 1829/2003. 
The EFSA GMO Panel was not requested to give a scientific opinion on information required under 
Annex II to the Cartagena Protocol. The EFSA GMO Panel did consider if there is a need for a 
specific labelling in accordance with Articles 13(2)(a) and 25(2)(c) of Regulation (EC) No 1829/2003. 
However,  it  did  not  consider  proposals  for  methods  of  detection  (including  sampling  and  the 
identification of the specific transformation event in the food/feed and/or food/feed produced from it), 
which are matters related to risk management. Scientific opinion on GM soybean 305423 
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ASSESSMENT 
1.  Introduction 
Soybean 305423 has been developed to increase the oleic acid content of seeds with the objective of 
improving  the  oxidative  stability  of  the  oil  as  a  result  of  the  reduced  polyunsaturated  fatty  acid 
(PUFA) content. Reduction in the expression of soybean enzyme omega-6 desaturase was achieved by 
introducing a fragment of the coding region of the corresponding gene (gm-fad2-1). An optimised 
soybean gene, gm-hra, that encodes acetolactate synthase (ALS) was also introduced into the soybean 
as a selectable marker conferring tolerance to ALS-inhibiting herbicides. 
The  gm-fad2-1  gene  fragment  inserted  in  soybean 305423,  under  the  control  of  a  seed-preferred 
promoter, corresponds to the middle of the coding region of the soybean fad2-1 gene. Transcription of 
this fragment results in silencing of the endogenous fad2-1 gene and leads to a decreased level of the 
corresponding fatty acid desaturase. As a consequence, the conversion of oleic acid to linoleic acid is 
inhibited and the oleic acid level is elevated. Since linolenic acid is produced from linoleic acid, 
linolenic acid content is also decreased in soybean 305423. 
The  second  modification  in  soybean 305423  confers  tolerance  to  sulphonylureas  and  some  other 
herbicide classes. ALS, also known as acetohydroxyacid synthase (AHAS), is the primary target for 
these herbicides. 
Soybean 305423 will be used for the production of soybean products as any commercial soybean 
variety. The main product for human use is soybean oil. In addition, soybean is used for the production 
of soybean milk, soybean protein isolate, flour, sprouts, baked or roasted soybeans, tofu, soybean 
sauce and other products for human consumption. Dehulled, fat-extracted toasted soybean meal is 
used as a source of protein in animal feed, sometimes in combination with soybean hulls. There is also 
a limited direct use of full-fat soybeans as animal feed. 
All food, feed and processed products derived from soybean 305423 are expected to replace a portion 
of similar products from commercial soybean. Oil from this soybean might also replace oils from 
sources other than soybean, particularly those used for commercial frying and spraying. 
2.  Issues raised by Member States 
The issues raised by the Member States are addressed in Annex G of the EFSA overall opinion
6 and 
have been considered in this scientific opinion. 
3.  Molecular characterisation 
3.1.  Evaluation of relevant scientific data 
3.1.1.  Transformation process and vector constructs
7 
Soybean 305423 was developed by particle bombardment of secondary somatic embryos derived from 
explants of small, immature soybean seed of cultivar Jack. Two gel-purified linear DNA fragments, 
PHP19340A  and  PHP17752A,  were  co-bombarded  into  embryogenic  soybean  cultures.  Both 
fragments were isolated from plasmids in which they were constructed. Complete sequences of the 
introduced fragments were provided. 
Fragment  PHP19340A  (2 924 bp)  contains  a  gm-fad2-1  gene  fragment  (597 bp)  from  the  coding 
region of the microsomal omega-6 desaturase gene 1 (fad2-1) of soybean; it does not code for a 
functional protein, but it is designed to silence the expression of the endogenous fad2-1 gene. The 
                                                       
6  Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2007-122 
7  Technical dossier/Sections C and D1. Scientific opinion on GM soybean 305423 
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seed-preferred  promoter  (2 084 bp)  and  the  terminator  (196 bp)  are  from  soybean  Kunitz  trypsin 
inhibitor gene 3 (KTi3). 
Fragment  PHP17752A  (4 512 bp)  contains  the  gm-hra  gene  (1 971 bp),  a  modified  form  of  the 
endogenous soybean als gene, which encodes ALS (GM-HRA). The protein confers tolerance to ALS-
inhibiting herbicides and was used as a selectable marker. Transcription is regulated by an S-adenosyl-
L-methionine synthetase (SAMS) promoter and the als gene terminator, both from soybean. 
3.1.2.  Transgene constructs in the GM plant
8 
Molecular characterisation of soybean 305423 to evaluate the insert copy number, insert integrity and 
presence of plasmid backbone was conducted by Southern analysis and the results were confirmed by 
sequencing  of the  inserted  DNA  from  soybean 305423.  For  Southern analysis,  leaf  samples  from 
soybean 305423 T4 (transgenic generation 4) and T5 generations were analysed. The T4 generation 
represents soybean 305423 obtained by four rounds of self-pollination of the original transformed Jack 
soybean line (T0). The T5 generation represents the following round of self pollination. 
The number and identity of the inserts were investigated not only by Southern analysis, but also by 
cloning of the inserts from plasmid and cosmid libraries and by polymerase chain reaction (PCR) 
amplification. Southern analyses were complicated by the fact that all introduced material was of 
soybean origin. The analyses, including additional information provided by the applicant, showed the 
presence  of  four  inserts  and  the  absence  of  all  elements  from  the  plasmid  backbone  (e.g.  the 
hygromycin resistance gene), except for a small, non-functional fragment. 
Multiple intact and truncated copies of fragment PHP19340A are present in  soybean 305423 that 
contain, in total, eight copies of the KTi3 promoter, seven copies of the gm-fad2-1 gene fragment and 
five  copies  of  the  KTi3  terminator.  A  single  intact  copy  of  fragment  PHP17752A  is  present  in 
soybean 305423.  Soybean 305423  has  a  rather  complex  insertion  arrangement,  containing  the 
following four insertions: 
Insertion 1: PHP19340A fragment with a truncated KTi3 terminator, intact gm-fad2-1 gene fragment 
and intact KTi3 promoter; intact PHP19340A fragment; intact PHP17752A fragment; PHP19340A 
fragment  with  an  intact  KTi3  promoter  and  a  truncated  gm-fad2-1  gene  fragment;  PHP19340A 
fragment with a truncated KTi3 promoter and truncated gm-fad2-1 gene fragment. 
Insertion 2: PHP19340A fragment with a truncated KTi3 promoter, intact gm-fad2-1 gene fragment 
and intact KTi3 terminator. 
Insertion 3: one copy of the KTi3 promoter with a non-functional 495 bp fragment of the plasmid 
backbone. 
Insertion 4: two truncated PHP19340A fragments in an inverted repeat configuration, both with a 
truncated KTi3 promoter and intact gm-fad2-1 gene fragment and KTi3 terminator. 
From the 5′ flanking region of the inserts 1, 2, 3 and 4, 7 000 bp, 7 599 bp, 2 439 bp and 2 899 bp 
were sequenced, respectively. From the 3′ flanking region of the inserts 1, 2, 3 and 4, 2 524 bp, 
2 737 bp,  2 287 bp  and  2 149 bp  were  sequenced,  respectively.  In  each  case,  BLASTn  sequence 
analysis resulted in significant identities to public and proprietary soybean genomic sequences. 
Open reading frames (ORFs) present in the junction regions and within the insert were analysed in 
soybean 305423.
9 All ORFs were considered from stop codon to stop codon. Similarities to known 
protein allergens and toxins wer e examined. No matches to known or putative allergens and no 
alignments to any known or putative toxins were found. The analysis also showed that there are no 
potential fusion proteins in soybean 305423 that raise safety concerns for human or animal health. 
                                                       
8  Technical dossier/Section D2. 
9  Additional information, May 2013. Scientific opinion on GM soybean 305423 
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3.1.3.  Information on the expression of the insert
10 
Northern analysis indicated an effective suppression of transcripts of both the endogenous fad2-1 gene 
and the introduced gm-fad2-1 gene fragment in soybean 305423 seeds. This was also reflected in the 
fatty acid profile of the plant. In addition, the KTi3 was silenced, which is explained by the fact that 
the KTi3 promoter was used to drive the expression of the gm-fad2-1 gene fragment. 
The levels of GM-HRA were analysed at six locations in the USA and in Canada (2005 growing 
season)  and  at  six  locations  in  Chile  and  Argentina  (2005–2006  growing  season)  by  a  specific 
enzyme-linked immunosorbent assay (ELISA) system developed for this protein. The mean level of 
the protein ranged from 2.1 to 2.5 μg/g seed dry weight and was not affected by spraying the plants 
with ALS-inhibiting herbicides. The protein was also present in the leaf, forage and root. 
3.1.4.  Inheritance and stability of the inserted DNA
11 
The inserted DNA in soybean 305423 is integrated in the soybean nuclear genome. Genetic stability 
was evaluated by studying the inheritance and segregation pattern of the introduced genetic material in 
several generations. Southern analysis using one restriction enzyme and gm-fad2-1 and gm-hra probes 
was performed on plants of the T4, T5 and F2 generations (T3 generation crossed to elite lines and 
selfed  once).  Stability  within  a  single  generation  was  studied  using  100  individuals  of  the  F2 
generation which were analysed for oleic acid content and by soybean 305423 event-specific PCR. 
One  plant  had  undergone  recombination  between  two  repeated  KTi3  promoter  elements  within 
insertion region 1, removing the entire gm-hra cassette and portions of the KTi3 promoter elements 
flanking  the  cassette.  Subsequent  studies  with  more  than  1 000  individuals  did  not  identify  any 
recombination events. It may be that insertion region 1 can be more prone to instability owing to the 
possibility of recombination between the two repeated KTi3 promoter elements. However, loss of part 
of region 1 does not raise any safety issue. 
The  inserted  DNA  is  genetically  linked  and  segregates  following  a  typical  pattern  of  Mendelian 
inheritance expected for a single, genetically linked insertion locus. Analysis of the GM-HRA protein 
and fatty acid profile of seeds collected across several locations in Chile, Argentina, the USA and 
Canada confirmed the phenotypic stability of the introduced traits. 
3.2.  Conclusion 
The molecular characterisation data establish that genetically modified (GM) soybean 305423 contains 
four complete and partial copies of the gm-fad2-1 and gm-hra expression cassettes. No other parts of 
the plasmid used for transformation are present in the transformed plant except for  a small, non-
functional  vector  fragment  which  does  not  include  the  origin  of  replication  or  the  hygromycin 
resistance gene. Results of updated bioinformatic analyses of the 5′ and 3′ flanking sequences and 
ORFs present in the junction regions and within the insert did not indicate a safety issue. One plant out 
of the 1 100 tested individuals had undergone recombination and, as a result, had lost the entire gm-
hra  cassette  and  portions of  the  promoter  elements flanking  the  cassette.  However,  the  Panel  on 
Genetically Modified Organisms of the European Food Safety Authority (EFSA GMO Panel) is of the 
opinion that this recombination, leading to loss of the trait, raises no safety issues. The stability of the 
inserted DNA was sufficiently confirmed over several generations. The four insertions are genetically 
linked and behave as a single Mendelian locus. 
4.  Comparative analysis 
4.1.  Evaluation of relevant scientific data 
The applicant performed the comparative assessment using the most recent statistical methodology 
recommended by the EFSA GMO Panel (EFSA GMO Panel, 2010a, 2011a). This recommends the 
simultaneous application of a test of difference to determine whether the GM plant is different from its 
                                                       
10 Technical dossier/Section D3. 
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conventional counterpart, and a test of equivalence to determine whether the GM plant falls within the 
natural variation estimated from the non-GM soybean reference varieties included in the study. As 
described  in  EFSA  (2011a),  the  result  of  the  equivalence  test  is  categor ised  into  four  possible 
outcomes  to  facilitate  the  drawing  of  conclusions  with  respect  to  the  presence  or  absence  of 
equivalence. These four categories are: category I, indicating full equivalence; category II, indicating 
that equivalence is more likely than non-equivalence; category III, indicating that non-equivalence is 
more likely than equivalence; and category IV, indicating non-equivalence. 
4.1.1.  Production of material
12 
The  applicant  provided  agronomic  and  compositional  data  from  field  trials  which  used  negative 
segregants as the only comparators. These field trials were performed at six locations in the USA and 
Canada in 2005 and at six locations during the season 2005–2006 in Chile and Argentina. As negative 
segregants are derived from a GM organism, the GMO Panel does not consider them as appropriate 
comparators with a history of safe use (EFSA, 2011a). 
On request of the EFSA GMO Panel, the applicant provided data for agronomic and phenotypic and 
compositional analyses where soybean 305423 was compared to the non-GM variety Jack, which is an 
appropriate conventional counterpart with a history of safe use. These additional data were from field 
trials carried out in the seasons 2005, 2010 and 2011 in North America.
13 The field trial in 2005 did 
not include GM soybean plants treated with the intended herbicide. The field trial carried out in 2010 
lacked sufficient statistical power because of insuf ficient replications. The 2011 field trial was 
performed at ten sites within soybean cultivation areas in the USA. At each site , the following test 
materials were grown in a random ised complete block design with four replicates:  soybean 305423 
treated and untreated with the intended herbicide, the conventional counterpart Jack and non -GM 
reference varieties (10 across all sites).
14 The EFSA GMO Panel considers that the 2011 field trial was 
performed in accordance with the most recent Guidance document (EFSA, 2011a) and data from this 
field trial formed the basis for the further assessment.  
4.1.2.  Agronomic and phenotypic characteristics
15 
Based on data collected at the ten sites in the USA field trial in 2011 (the same field trial used to 
collect  seeds  and  forage  for  compositional  studies,  see  sections  4.1.1  and  4.1.3),  the  applicant 
performed  a  comparative  assessment  of  the  agronomic  and  phenotypic  characteristics  of 
soybean 305423 and its conventional counterpart, as well as between soybean 305423 and the non-
GM  reference  soybean  varieties  grown  in  the  same  sites.  The  ten  agronomic  and  phenotypic 
characteristics  evaluated  were:  early  population,  final  population,  seedling  vigour,  plant  height, 
disease incidence, insect damage, lodging, shattering, days to maturity and yield.  
The  test  of  difference of the  agronomic  and  phenotypic  characteristics  of  soybean 305423 (either 
sprayed with maintenance pesticides or sprayed with the intended herbicide on top of the maintenance 
pesticide) compared with the conventional counterpart identified statistically significant differences 
for six  endpoints  (early  population, final population,  seedling  vigour,  plant  height,  shattering  and 
yield). The equivalence test indicated that all the characteristics analysed (except for shattering
16) fell 
within the equivalence limits established from the non -GM soybean reference varieties. Considering 
these outcomes of the equivalence test and the type of characteristics, the GMO Panel found that the 
identified differences are not an indication for an unintended effect that would significantly impact on 
crop biology.  
                                                       
12 Technical Dossier/Sections D7.2 and D7.3 and additional information, March 2012. 
13 Additional information, February 2008 and 2011 and March 2012. 
14 Pioneer® Brand Soybean Line 92M10, Pioneer® Brand Soybean Line 92M22, Pioneer® Brand Soybean Line 92M72, 
Pioneer® Brand Soybean Line 92Y21, Pioneer® Brand Soybean Line 93B82, Pioneer® Brand Soybean Line 93M14, 
Pioneer® Brand Soybean Line 93M5, Pioneer® Brand Soybean Line 93M62, Pioneer® Brand Soybean Line 93Y21, 
Pioneer® Brand Soybean Line 93Y41. 
15 Technical Dossier/Section D4 and additional information, January 2012. 
16 The test of equivalence could not be performed on shattering because of the lack of variation among the non-GM reference 
varieties for this endpoint. Scientific opinion on GM soybean 305423 
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4.1.3.  Compositional analysis
17 
The key constituents included in the compositional analysis of soybean seeds and forage were in 
accordance  with  Organisation  for  Economic  Co-operation  and  Development  (OECD) 
recommendations  (OECD,  2001).  Specific  fatty  acids  were included  because  of the  nature  of  the 
genetic modification. In total,  92 endpoints were measured in seeds and seven were measured in 
forage.  Nineteen  parameters  having  more  than  50 %  of  the  observations  below  the  limit  of 
quantification were excluded from the comparative analysis. In total, 73 parameters were statistically 
analysed in seeds and seven were analysed in forage.
18  
Plants  sprayed  with  maintenance  pesticides  showed  statisticall y  significant  differences  between 
soybean 305423 and its conventional counterpart for 51 parameters in seeds and  four parameters in 
forage  (crude fat, crude fib re, neutral detergent fib re  and acid detergent fib re).  For differences 
observed in 34 out of the 51 seed parameters, no further assessment was required, because they fell 
within the equivalence limits established from the non-GM soybean reference varieties included in the 
study. Equivalence could not be established for 16 of the 51 seeds ’ parameters (equivalence category 
III or IV). These compounds were myristic acid, palmitic acid, heptadecanoic acid, heptadecenoic 
acid, oleic acid, linoleic acid, linolenic acid, isomer 2 of nonadecenoic acid, arachidic acid, eicosenoic 
acid,  behenic  acid,  lignoceric  acid,  zinc,  glycitin,  total  glycitein  equivalents  and  trypsin  inhibitor 
(Table 1). The test of equivalence could not be performed on one of the 51 seeds’ parameters showing 
statistically significant differences, namely (9,15) isomer of linoleic acid (C18:2), because of the lack 
of variation among the non-GM soybean reference varieties for this compound. Equivalence could not 
be established for two forage parameters (neutral detergent fibre and acid detergent fibre) that showed 
significant  differences  (equivalence  category  III)  (Table  1).  The  test  of  equivalence  could  not  be 
performed on one forage parameter showing a significant difference (crude fibre) because of the lack 
of variation among the non-GM soybean reference varieties for this compound. 
Samples  sprayed  with  the  intended  herbicide  in  addition  to  the  maintenance  herbicide  showed 
statistically significant differences between soybean 305423 and its conventional counterpart (sprayed 
with the maintenance pesticides) for 53 compounds in seeds and three compounds in forage (crude 
fibre, neutral detergent fibre and acid detergent fibre). The test of equivalence indicated that 36 of the 
53  parameters  in  seeds  fell  within  the  equivalence  limits  established  from  the  non-GM  soybean 
reference  varieties.  Equivalence  could  not  be  established  for  16  of  the  53  seeds’  parameters 
(equivalence  categories  III  and  IV).  These  compounds  were  myristic  acid,  palmitic  acid, 
heptadecanoic  acid,  heptadecenoic  acid,  oleic  acid,  linoleic  acid,  linolenic  acid,  isomer  2  of 
nonadecenoic  acid,  arachidic  acid,  eicosenoic  acid,  behenic  acid,  lignoceric  acid,  glycitin,  total 
glycitein equivalents, trypsin inhibitor and calcium (Table 1). The test of equivalence could not be 
performed on one of the 53 statistically significantly different seeds’ parameters (acid detergent fibre) 
because of the lack of variation among the non-GM soybean reference varieties for this compound. 
Equivalence  could  not  be  established  for  one  of  the  three  forage  parameters  showing  significant 
                                                       
17 Technical Dossier/Sections D7.2 and D7.3 and additional information, March 2012. 
18 Compounds having quantifiable levels in seeds were: proximates and fibre fractions (crude protein, crude fat, crude fibre, 
acid detergent fibre, neutral detergent fibre, ash, carbohydrates (by calculation)), fatty acid profile (myristic acid, palmitic 
acid, palmitoleic acid, heptadecanoic acid, heptadecenoic acid, stearic acid, oleic acid, linoleic acid, (9,15) isomer of 
linoleic acid, linolenic acid, isomer 2 of nonadecenoic acid, arachidic acid, eicosenoic acid, behenic ac id, tricosanoic acid, 
lignoceric acid), total amino acids (alanine, arginine, aspartic acid, cystine, glutamic acid, glycine, histidine, isoleucine, 
leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine), mine rals (calcium, 
copper, iron, magnesium, manganese, phosphorus, potassium, zinc), vitamins (vitamin B1, vitamin B2, vitamin B3, 
vitamin  B5,  vitamin  B6,  vitamin  B9,  ʱ-tocopherol,  β-tocopherol,  γ-tocopherol,  ʴ-tocopherol,  total  tocopherols), 
antinutrients  and  other  secondary  compounds  (daidzein,  daidzin,  genistin,  glycitin,  total  daidzein  equivalents  (by 
calculation), total genistein equivalents (by calculation), total glycitein equivalents (by calculation), raffinose, stachyose, 
sucrose, lectins, phytic acid and trypsin inhibitor). Compounds analysed in forage were proximates and fibre fractions 
(crude protein, crude fat, crude fibre, acid detergent fibre, neutral detergent fibre, ash and carbohydrates (by calculation)). 
Compounds where 50 % or more sample values were below the lower limit of quantification in seed were: caprylic acid 
(C8:0), capric acid (C10:0), lauric acid (C12:0), myristoleic acid (C14:1), pentadecanoic acid (C15:0), pentadecenoic acid 
(C15:1), heptadecadienoic acid (C17:2), γ-linolenic acid (C18:3), nonadecanoic acid (C19:0), isomer 1 of nonadecenoic 
acid  (C19:1),  eicosadienoic  acid  (C20:2),  eicosatrienoic  acid  (C20:3),  arachidonic  acid  (C20:4),  heneicosanoic  acid 
(C21:0), erucic acid (C22:1), sodium, genistein, glycitein, coumestrol. Scientific opinion on GM soybean 305423 
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differences (neutral detergent fibre; equivalence category III). The test of equivalence could not be 
performed on one forage parameter showing a significant difference (crude fibre) because of the lack 
of variation among the non-GM soybean reference varieties for this compound (Table 1).  
Table 1 shows the mean values for  the  endpoints which were statistically different and  fell  into 
equivalence categories III and IV. The observed differences of the fatty acid profile are consistent with 
the intended effect of the genetic modification, i.e. an increase in oleic acid at the expense of PUFA. 
Changes  in  the  levels  of odd  chain  fatty  acids  are  an  unintended  effect probably  caused  by  the 
introduction of the ALS enzyme. An explanation provided by the applicant , which  is  considered 
plausible by the EFSA GMO Panel, is that the newly introduced GM-HRA enzyme, acting in a similar 
way to ALS to confer herbicide tolerance, may have a decreased affinity for 2-ketobutyrate owing to 
the replacement of tryptophan 560 by leucine. The decreased affinity of the GM-HRA enzyme for 2-
ketobutyrate may lead to higher concentrations of 2-ketobutyrate in soybean 305423. As the odd chain 
fatty acid biosynthesis starts with the conversion of 2-ketobutyrate to propionyl-CoA, followed by the 
subsequent addition of C2 moieties, an increased pool of 2-ketobutyrate available for odd chain fatty 
acid biosynthesis may lead to increased levels of such fatty acids. The changed fatty acid profile is 
assessed for possible nutritional and safety implications in section 5.  
The other parameters (calcium, zinc and glycitin and related total glycitein equivalents) showing non-
equivalence were further evaluated by the EFSA GMO Panel. The Panel took into account their well-
known biochemical roles and the magnitude of the reported levels and concluded that the reported 
levels lack relevance from a food and feed safety and nutritional point of view. The EFSA GMO Panel 
noted that the variation for glycitin in soybean exceeds the lower and upper limits established by the 
non-GM  reference  varieties  growing  in  the  same  field  trial  (Al-Tawaha  et  al.,  2007;  Gutierrez-
Gonzalez et al., 2009). 
The  lack  of  equivalence  for  trypsin  inhibitor  was  the  result  of  a  decrease  of  its  level  in 
soybean 305423. This is in line with the Northern analysis results indicating silencing of the trypsin 
inhibitor gene transcription in  soybean 305423  seed.  A  decreased level of trypsin inhibitor is  not 
posing any safety concern. 
For the differences in forage  fibre fractions for which equivalence could not be established or the 
equivalence test could not be performed, the EFSA GMO Panel considered that, based on the well-
known biochemical properties of fibre fractions and the magnitude of levels in forage, these endpoints 
do not require further assessment. 
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Table 1:   Levels of constituents in forage and seeds harvested from field trials with soybean 305423 
and the conventional counterpart Jack, which were statistically significantly different between 305423 
and Jack and which fell into equivalence categories III and IV  
Constituents  Means and standard deviations (in brackets) across 
locations (2011 field trial) 
Conventional 
counterpart 
(Jack) 
Soybean 305423 
(untreated) 
Soybean 305423 
(treated) 
Equivalence category IV 
Saturated fatty acids 
(a) 
Myristic acid (C14:0)  0.07 (0.012)  0.04 (0.010)  0.04 (0.010) 
Palmitic acid (C16:0)  10.1 (0.283)  6.48 (0.295)  6.50 (0.334) 
Heptadecanoic acid (C17:0)  0.11 (0.036)  0.81 (0.013)  0.81 (0.054) 
Arachidic acid (C20:0)  0.32 (0.029)  0.42 (0.029)  0.42 (0.028) 
Behenic acid (C22:0)  0.33 (0.038)  0.43 (0.025)  0.43 (0.034) 
Tricosanoic acid (C23:0)  0.053 (0.012)  0.064 (0.010)  0.065 (0.014) 
Lignoceric acid (C24:0)  0.14 (0.036)  0.20 (0.024)  0.19 (0.035) 
Mono-unsaturated fatty acids 
(a) 
Heptadecenoic acid (C17:1)  0.06 (0.036)  1.26 (0.013)  1.26 (0.013) 
Oleic acid (C18:1)  19.2 (2.531)  73.7 (1.836)  72.7 (4.626) 
Isomer 2 nonadecenoic acid (C19:1) 
(b)  0.04 (0.038)  0.31 (0.027)  0.32 (0.040) 
Eicosenoic acid (C20:1)  0.17 (0.046)  0.35 (0.023)  0.35 (0.046) 
Polyunsaturated fatty acids 
(a) 
Linoleic acid (C18:2)  54.9 (1.723)  4.26 (1.619)  4.48 (2.753) 
Linolenic acid (C18:3)  8.28 (0.950)  4.84 (0.939)  4.72 (1.062) 
Other constituents 
Zinc [% DW]  0.005 (0.001)  0.006 (0.001)  0.005 (0.001) 
Trypsin inhibitor [IU/mg DW]  29.4 (2.964)  13.8 (5.038)  14.6 (2.009) 
Equivalence category III 
Other constituents 
Acid detergent fibre [% DW]
19  33.7 (2.031)  31.5 (1.424)  31.6 (2.092) 
Neutral detergent fibre [% DW]
19  44.0 (1.079)  41.3 (1.458)  41.6 (0.889) 
Calcium [% DW]  0.26 (0.031)  0.24 (0.046)  0.23 (0.027) 
Glycitin [mg/kg DW]  310 (28.949)  423 (20.309)  418 (35.112) 
Total Glycitein [mg/kg DW]  200 (18.542)  272 (12.752)  270 (21.417) 
(a):  Fatty acid proportions are given as percentages of total fatty acids. Soybean 305423 was either treated with intended 
herbicide (treated) or treated with conventional herbicide (untreated). 
(b):  Position of the double bond in nonadecenoic acid not known. 
4.2.  Conclusion 
The EFSA GMO Panel concludes that the composition of soybean 305423 differs from that of the 
conventional  counterpart  and  of  non-GM  reference  varieties  in  its  fatty  acid  profile,  the  newly 
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expressed protein, the minerals zinc and calcium and the isoflavone glycitin. The variations in the fatty 
acid profile and the newly expressed protein are consistent with the objective of the modification as 
well  as  with  the  expression  of  the  ALS  enzyme  of  soybean 305423.  A  safety  and  nutritional 
assessment of the altered fatty acid profile and the newly expressed protein is provided in section 5 of 
this Scientific Opinion. For the remaining compounds, no further assessment was deemed necessary 
owing to their well-known biochemical roles and to the magnitude of the reported levels. 
The EFSA GMO Panel also concludes that no differences were identified in the agronomic and 
phenotypic characteristics that would require further assessment with regard to safety. 
5.  Food/feed safety assessment 
5.1.  Evaluation of relevant scientific data 
5.1.1.  Effects of processing
20 
No novel method of production and processing is envisaged. 
The applicant studied the influence of temperature (36–60  C) and pH value (5.0–9.0) on the enzyme 
activity of the GM-HRA protein produced in Escherichia coli (see section 5.1.2.1) using an ALS 
activity assay based on the production of acetolactate from pyruvate. After incubation at 44  C for 15 
minutes, approximately 50 % of the activity was lost, and the enzyme was inactivated after incubation 
at 50  C for 15 minutes. The optimal pH for the enzyme activity was in the range pH 7.0–7.5, whereas 
there was practically no activity at or below pH 6.0 as well as at pH 9.0. 
5.1.2.  Toxicology
21 
5.1.2.1.  Protein used for safety assessment
22 
The only newly expressed protein in soybean 305423 is the GM-HRA protein. Given its low levels of 
expression in soybean 305423, GM-HRA protein produced in a recombinant  E. coli strain (BL21 
(DE3)RIPL) was used for the safety assessment. 
The mature form of the GM-HRA protein, not containing the N-terminal chloroplast transit peptide 
cleaved from the protein during processing in the plant, was produced in E. coli in the form of a fusion 
protein. The purification process included the cleavage of the His-tag with thrombin; the resulting 
microbial GM-HRA protein has an additional glycine residue at the N-terminus (resulting in a total of 
604 amino acids) compared with the mature GM-HRA protein expressed in soybean 305423 leaves. 
The  equivalence  of  the  GM-HRA  protein  produced  in  E.  coli  to  that  produced  in  leaf  tissue  of 
soybean 305423 was shown by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE)  and  protein  staining,  Western  analysis,  N-terminal  amino  acid  sequence  analysis,  matrix-
assisted laser desorption/ionisation mass spectrometry (MALDI-MS) analysis of tryptic peptides and 
glycosylation  analysis.  In  addition,  the  identity  of  the  microbial  protein  was  corroborated  using 
electrospray ionisation mass spectroscopy, analysis of the amino acid composition and determination 
of the enzyme activity. 
Based on the identified similarity in structure and equivalence in physico-chemical properties and 
function between microbial and soybean 305423 GM-HRA proteins, the EFSA GMO Panel accepts 
the use of GM-HRA produced in E. coli as an appropriate substitute test material for the GM-HRA 
protein present in soybean 305423. 
                                                       
20 Technical Dossier/Section D7.6. 
21 Technical Dossier/Section D7.8 and additional information, October 2010 and April 2011. 
22 Technical Dossier/Section D7.8.1. Scientific opinion on GM soybean 305423 
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5.1.2.2.  Toxicological assessment of the expressed novel protein in soybean 305423
23 
The GM-HRA protein expressed in soybean 305423 is an ALS encoded by a modified als gene from 
soybean (Glycine max). 
The EFSA GMO Panel has previously evaluated the safety of the GM-HRA protein in the context of 
application EFSA-GMO-UK-2007-43, which included an acute and a 28-day repeated-dose toxicity 
study in mice and in vitro pepsin- and pancreatin-resistance tests. No safety concerns were identified 
(EFSA, 2011b). 
The  bioinformatics-supported  comparison  of  the  amino  acid  sequence  of  the  GM-HRA  precursor 
protein expressed in soybean 305423 has been updated (February 2013) and revealed no significant 
similarities to known toxic proteins.
24 
5.1.3.  Animal studies with the food/feed derived from soybean 305423 
The applicant performed a 95-day feeding study in rats, a 42-day study in chickens for fattening, a 12-
week study in laying hens and a 77-day study in pigs using diets containing processed fractions of 
soybean 305423 or control soybean. Dehulled, fat-extracted toasted soybean meal was the principal 
product tested, with small amounts of hulls and/or oil added in the rat and chicken studies. In the rat 
and chicken studies, the applicant used as  a control soybean products from a negative segregant. 
Additional groups were fed with commercial non-GM soybean varieties.
25 
5.1.3.1.  Sub-chronic toxicity study in rats
26 
Groups of 12 male and 12 female Crl:CD(SD) rats, individually housed, were ad libitum fed balanced 
rodent  diets  for  95  days  incorporating  dehulled  fat-extracted  toasted  soybean  meal  (19.8–20 %), 
toasted  ground  hulls  (1.43–1.5 %)  and  degummed  alkaline-refined  oil  (1.53–1.73 %)  derived, 
respectively, from soybean 305423 (test group, verified by PCR), a negative segregant (control group); 
and  commercial  non-GM  soybean  varieties  (93B86,  93B15  or  93M40).  Soybean 305423  was  not 
treated with the intended herbicide.
27 All soybean fractions and diets were nutritionally similar, with 
the expected fatty acids level changes in 305423 oil and diet . Effects of 305423 diet on standard 
endpoints (OECD 408) were compared by analysis of variance (ANOVA) with those from control. 
Data from animals fed commercial varieties were used to obtain information on the normal range of 
the examined parameters. 
There were no deaths during the study. Regular observations of the animals did not revea l clinically 
relevant effects. Apart from some isolated statistically significant differences between the test and 
control group, body weight, body weight gain, feed consumption and feed efficiency were  similar 
across all groups. Ophthalmological as well as neurobehavioral evaluations (an abbreviated functional 
observational battery and motor activity measurements) showed no relevant differences between 
groups. Haematology, coagulation and clinical chemistry analyses showed no statistically significant 
differences between the test and control group. Urinalysis findings were unremarkable. A statistically 
significant lower heart weight (relative to brain weight) was seen in  males fed the  test diet in 
comparison with controls. This was not accompanied by changes in other cardiac endpoints (absolute 
and relative-to-body organ weight; macroscopic or microscopic findings) and is considered incidental. 
No  relevant  differences  between  group s  were  seen  at  macroscopic  examination.  Microscopic 
examination was only performed in the test and control group, and the nature and the incidence of the 
findings were similar and typical for animals of this strain and age. 
The EFSA GMO Panel considers that a repeated -dose 90-day oral toxicity study, in which material 
derived from a negative segregant is administered as the sole control material, has limitations for the 
                                                       
23 Technical dossier/Section D1. 
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safety assessment, principally because of an inability to detect unintended effects. An appropriate non-
GM genotype with a genetic background as close as possible to soybean 305423 with a history of safe 
use (conventional counterpart) should have been included in this study. However, three commercial 
non-GM varieties were included providing information on the normal range. The values and/or nature 
of the findings were comparable throughout all groups.  
5.1.3.2.  Chicken feeding study
28 
The  applicant  provided  a  42 -day  study,  which  was  also  described  in  a  scientific  publication 
(McNaughton et al., 2008 ). Six hundred commercial Ross   Cobb broilers were assigned to five 
experimental groups (n = 60/sex/group, housed five per sex and per pen for a total of 12 pens per 
group) fed diets containing processed products, respectively, from soybean 305423 (test group), the 
negative segregant (control group) or commercial non-GM varieties (993B86, 93B15 and 93M40). 
Soybean 305423  was  not treated  with  the  intended herbicide.
29  Chickens were offered  ad  libitum 
starter (days 0 to 21), grower (days 22 to 35) and finisher diets (days 36 to 42) with, respectively, 
26.5 %, 23 % or 21.5 % toasted soybean meal and fixed amount of soybean hulls and oil (1 % or 
0.5 %, respectively); hulls and oil were in a lower proportion than in conventional formulations owing 
to their different nutritional values in comparison with the typical commercial counterparts (higher 
hull nutritional values and lower oil gross energy values). Before mixing the feed, meals and hulls 
were  analysed  for  proximates  and  minerals,  amino  acids,  mycotoxins  and  oils  for  fatty  acid 
composition.  Diets  were  adjusted  according  to  the  National  Research  Council  (NRC)  Nutrient 
Requirement for Poultry (1994) to be isonitrogenous, isocaloric and balanced for minerals, sulphur 
and limiting amino acids (analytically confirmed). PCR confirmed the presence of the DP-305423-1 
event  in  the  soybean 305423  diet  only.
30  The  GM-HRA  protein  was  below  the  low  limit  of 
quantification (< 0.27 ng/mg). 
Effects of  soybean 305423  diet on health status, survival, body weight and feed intake (taken at 
weekly intervals), body weight gain and feed efficiency (calculated from  day 0 to day 42), terminal 
carcass and carcass parts  weight from four chicken/sex/pen (thighs, breasts, wings, legs, abdominal 
fat; kidneys and liver as indicators of health from dietary inadequacies) were compared  with those 
from  control.  Statistical  ana lysis  was  performed  by  a  mixed  ANOVA  using  the  pen  as  the 
experimental unit for health status, survival, body   weight,  body  weight  gain,  feed  intake,  feed 
efficiency and terminal live weight without considering sex, using instead individuals for carcass data, 
taking into account the sex. For statistically significant differences (P ≤ 0.05) the Benjamin–Hochberg 
analysis for false discovery rate was applied. Data from animals fed commercial varieties were used to 
obtain 95 % tolerance ranges. 
An overall low mortality was observed (0.83–1.67 %), with equal values for controls and test diet 
groups (1/120). Final body weights and body weight gain (day 0–42) from test diet fed chicken were 
slightly  lower  in  comparison  with  concurrent  controls  (body  weight:  1862.3 g  test  diet,  1905.5 g 
control diet; body weight gain: 1814.4 g test diet, 1857.4 g control diet); however, these differences 
were not statistically significant and within the 95 % tolerance range derived from the  additional 
groups fed commercial non-GM varieties. Significant differences in feed per gain ratio (1.87 test diet, 
1.86 control diet) or in any carcass yield data were not obtained. 
The EFSA GMO Panel considers that a 42-day feeding study in broilers, in which material derived 
from  a  negative  segregant  is  administered  as  the  sole  control  material,  has  limitations  for  the 
nutritional assessment, principally because of an inability to detect unintended effects. The use of low 
energy diets (about 3–3.5 % fat) further reduced the capacity of the study to detect unintended effects. 
As the diets were formulated to provide the same nutrition, the expectation was that chicken from the 
                                                       
28 Technical dossier/Annex 9 and additional information, October 2012. 
29 Additional information, May 2013/Annex 6. 
30 A low-level contamination by MON-04032-6 event was detected in six out of twelve determinations of the grower soybean 
305423 test diet. The MON-04032-6 event is associated with the expression of cp4 epsps protein which confers herbicide 
tolerance via a different mechanism of action. It is therefore considered  that any influence on the zootechnical results  is 
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five  experimental  groups  would  show  essentially  the  same  performance  characteristics.  Results 
confirmed the nutritional value of soybean toasted defatted meal derived from soybean 305423, as the 
zootechnical  performance  parameters  of  the  test  group  were  within  the  95  %  tolerance  intervals 
derived from the three commercial non-GM varieties. 
5.1.3.3.  Laying hen feeding study
31 
A 12-week feeding study (composed of three 4-week phases according to egg production stage) was 
conducted on Hy-Line W-36 Single Comb White Leghorn hens (Mejia et al., 2010). Pullets (n = 336, 
20 weeks old) were placed in 24 experimental units (cage lots, with two cages/lot, seven hens/cage), 
which were randomly assigned to four groups (six cage lots/group). After a 5-week adaptation period, 
hens  were  fed  diets  containing  22.95–23.87 %  dehulled  fat-extracted  toasted  soybean  meals  from 
305423  (test  group,  PCR  confirmed),  the  conventional  counterpart  Jack  (control  group)  and 
commercial non-GM varieties (92M72 and 93B15). Compositional data were provided only for the 
soybean meals used in the study. Only soybean 305423 was treated with the intended herbicide.
32 
Balanced diets were formulated according to NRC (1994) to be isonitrogenous and isocaloric (GE), 
with  further  adjustments  for  sulphur  amino  acids,  lysine,  threonine,  tryptophan  and  arginine 
(analytically confirmed). Commercial soybean oil (1.2 %) was added to all diets. 
Zootechnical performance and egg quality parameters were recorded and calculated on a phase basis. 
The comparison between soybean 305423 and control groups was conducted on summarised overall 
study  data.  Statistical  analysis  was  based  on  a  mixed  model  with  treatment,  phase  and 
treatment   phase interaction as fixed effects   and  cage lot as  a  random effect.  For statistically 
significant differences ( P ≤ 0.05)  the  Benjamin–Hochberg  analysis  for  false  discovery  rate  was 
applied. Data from commercial non-GM varieties fed animals were used to obtain 95 % tolerance 
intervals. 
Sporadic mortalities occurred in the groups fed with soybean 305423, control and 92M7 groups (one 
hen/group). Apart from an incidental decline in production (egg/hen/day and egg mass) seen in one 
cage lot fed soybean 305423 diet during the second and third study phase owing to a few individuals 
going out of production, no significant differences in performance and egg quality parameters were 
seen between hens fed the 305423 and the control diets. 
As the diets were formulated to provide the same nutrition, the expectation was that hens from the four 
experimental groups would show essentially the same performance characteristics. Results confirmed 
the nutritional  value  of  soybean  toasted  defatted  meal and the  absence  of  any  unintended effects 
impacting on performance at the tested level. 
 
5.1.3.4.  Pig feeding study
33 
In a 77-day feeding  study (Miller et al., 2011), 64 individually housed  pigs, 27 kg weight,  were 
randomly allocated to four groups (eight animals/sex/group). The experiment took place in two rooms 
of  a  single  environmentally  controlled  barn,  with  treatment  replicates  blocked  by  room  ( four 
animals/sex/group/room). This study followed a three -phase programme (grower phase, days 1–34; 
early finisher phase, days 35–62; and late finisher phase, days 63–77). The grower, early finisher and 
late finisher diets, formulated and balanced (analytically confirmed) according NRC (1998), contained 
24.23–26.44 %, 19.58–20.71 % or 14.95–16.27 % soybean meal, respectively, and were offered in 
mash  form  ad  libitum.  The  four  experimental  groups  received  diets  with  305423  (test  diet,  PCR 
confirmed),  conventional  counterpart  Jack  (control  diet)  and  two  non-GM  commercial  soybean 
                                                       
31 Additional information, May 2013, and Mejia et al., 2010. 
32 Additional information, May 2013/Annex 7. 
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varieties (92M72; 93B15). Compositional data were provided for only the soybean meals used in the 
study. Only soybean 305423 was treated with the intended herbicide.
34,35 
Pigs were weighed at  the beginning of the experiment and on days 14, 35, 49, 63 and 77. Feed 
allocation  was  recorded  daily.  Comparison  between  test  diet-  and  control  diet-fed  animals  was 
performed on zootechnical performance measures (final body weight, average daily gain, average feed 
daily intake and gain-to-feed ratio) and on carcass data (dressing percentage, hot weight, tenth rib 
backfat thickness, loin eye area, lean meat percentages, loin depth measured at the tenth rib). The 
individual pig was the experimental unit for the data analysis, which was conducted on sex-combined 
data. A mixed ANOVA model was used for the analysis, with treatment, sex and treatment   sex 
interaction as fixed effects and room assignment as a random effect in the analysis of growth and 
carcass data (also harvest day as a random effect). For statistically significant differences (P ≤ 0.05) 
the Benjamin–Hochberg analysis for false discovery rate  was applied. Data from  animals fed the 
additional commercial varieties were used to obtain 95 % tolerance intervals. 
Two incidental barrow mortalities occurred (diagnosed as Salmonella infection-related, one control 
from one room, and one test diet barrow from the other room) and one control female showed poor 
feed intake and weight loss throughout the study, despite antibiotic treatment, and were eventually 
dropped  from  the  statistical  analysis.  No  significant  differences  (false  discovery  rate  adjusted 
P < 0.05) were found for all endpoints examined. 
As the diets were formulated to provide the same nutrition, the expectation was that pigs from the four 
experimental groups would show essentially the same performance characteristics. Results confirmed 
the nutritional value of soybean toasted fat-extracted meal and the absence of any unintended effects 
impacting on performance at the tested level. 
5.1.4.  Allergenicity
36 
The strategies used when assessing the potential allergenic risk focus on the characterisation of the 
source  of  the  recombinant  protein(s),  the  potential  of  the  newly  expressed  protein(s)  to  induce 
sensitisation or to elicit allergic reactions in already sensitised persons and whether the transformation 
may have altered the allergenic properties of the modified plant. 
5.1.4.1.  Assessment of allergenicity of the newly expressed protein
37 
A weight-of-evidence approach is recommended, taking into account all of the information obtained 
with various test methods, as no single experimental method yields decisive evidence for allergenicity 
(EFSA, 2006a; Codex Alimentarius, 2009). 
The EFSA GMO Panel has previously evaluated the safety of the GM-HRA protein in the context of 
application  EFSA-GMO-UK-2007-43  and  no  concerns  on  allergenicity  were  identified  ( EFSA, 
2011a). 
Updated bioinformatic analyses
38 of the amino acid sequence of the GM-HRA precursor protein using 
the criterion of 35 % identity in a window of 80 amino acids revealed no significant similarities to 
known  allergens.  In  addition,  the  applicant  performed  analyses
39  searching for matches of eight 
contiguous identical amino acid sequences between  the  GM-HRA  precursor  protein  and  known 
allergens, which confirmed the outcome of the previous bioinformatic analyses. 
                                                       
34 Additional information, May 2013/Annex 6. 
35 Additional information, May 2013/Annex 7. 
36 Technical dossier/Section D7.9 and additional information, October 2010. 
37 Technical dossier/Section D7.9.1 and additional information, May 2013. 
38 Additional information, May 2013. 
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Based on all the information available, the EFSA GMO Panel considers that there are no indications 
that the protein GM-HRA present in soybean 305423 may be allergenic in the intended conditions of 
use. 
5.1.4.2.  Assessment of allergenicity of the whole GM plant or crop 
Allergenicity of the whole GM plant could be increased as an unintended effect owing to the genetic 
modification,  for  example  through  qualitative  or  quantitative  modifications  of  the  pattern  of 
expression of endogenous proteins. 
According to the EFSA GMO Panel Guidance document (EFSA, 2006a), when the plant receiving the 
introduced  gene  is  known  to  be  allergenic,  the  applicant  should  test  any  potential  change  in  the 
allergenicity of the whole GM plant by comparing the allergen repertoire with that of its appropriate 
conventional counterpart(s). In this context, soybean is also considered a common allergenic food (EC, 
2007). 
Initially,  the  applicant  performed  in  vitro  allergenicity  studies  with  extracts  of  seeds  from 
soybean 305423  and  its  conventional  counterpart.  The  applicant  provided  one-dimensional  (1-D) 
immunoglobulin (IgE) immunoblot analysis as well as ELISA inhibition tests using pooled sera from 
individuals allergic to soybean. Based on these data only, the EFSA GMO Panel could not conclude 
on the endogenous allergenicity of soybean 305423 owing to the limitations associated with these two 
methodologies (see Annex 4 and Annex 5 of EFSA GMO Panel, 2010b). 
At  the  request  of  the  EFSA  GMO  Panel,  the  applicant  provided  additional  information  (2-D 
immunoblot and ELISA analyses) using individual sera from eight subjects with clinically confirmed 
allergy to soybeans and five negative control sera. In the 2-D immunoblot analysis, no meaningful 
differences in the IgE binding patterns were detected between extracts of  soybean 305423 and its 
conventional  counterpart.  In  the  ELISA  analysis,  the  sera  from  allergic  individuals  had  similar 
reactivity to proteins in extracts from soybean 305423 and the conventional counterpart. 
In the context of the present application, and based on all the available information, the EFSA GMO 
Panel concludes that there are no indications that the genetic modification might significantly change 
the overall allergenicity of soybean 305423 when compared with that of its conventional counterpart. 
5.1.5.  Nutritional assessment of GM food/feed  
5.1.5.1.  Human exposure 
The main product for human consumption is the oil of soybean 305423, which has a high content of 
oleic acid and a reduced content of PUFA. It is intended for use in commercial frying and spraying 
only.
40 Concerning this use, the applicant provided three different exposure scenarios exclusively for 
fried foods.
41 Subsequently, the applicant provided a f ourth scenario covering the use of this oil in 
targeted foods and other foods.
42 The Panel has considered the last scenario only, because it covers the 
greatest number of food items, and it is therefore more conservative. 
Consumption data are taken from the UK National Diet and Nutrition Survey (NDNS) of 2008–2010 
(Bates et al., 2011). The sub-populations considered are toddlers (1–3 years), children (4–10 years), 
teenagers (11–18 years), adults (19–64 years) and the elderly (≥ 65 years). The content of a specific 
vegetable oil in foods was calculated. Food items considered are the targeted foods (fried fish, meat, 
potatoes, vegetables and other fried foods, home-use; and from spray applications savoury snacks and 
crackers) and other foods (salad dressings, margarines and spread, mayonnaise).  
                                                       
40 Technical dossier/Section D7.10.1 and additional information, November 2008. 
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The fatty acid composition of the oil from soybean 305423 is taken from that of the unprocessed seeds 
from the field trial of 2011.
43 The oil is assumed to fully replace vegetable oils in the individual food 
items.
44 Vegetable oils considered were rapeseed oil, sunflower oil, palm oil and blends of these oils. 
Whenever the type of vegetable oil could not be identified, composite oil with an equal blend of high-
oleic sunflower, palm and canola oil was assumed. 
This enabled an assessment of  estimated daily  intakes from both domestically and commercially 
prepared foods. Results are given as means and expressed as g/day (Table  2) and as  percentage of 
energy  (E %)  of the total diet (Table  3) for five fatty acid groups ( saturated  fatty acids (SFA), 
monounsaturated fatty acids (MUFA), n-6 PUFA, n-3 PUFA and trans fatty acids (TFA)). Average 
and upper percentile intake amounts of the relevant food groups were calculated. 
Table 2:   Estimated daily intake (g) of fatty acid groups before (B) and after (A) the replacement of 
the vegetable oils with the soybean 305423 oil  
Consumer 
group 
(a) 
Mean SFA  Mean MUFA  Mean n-6 PUFA  Mean n-3 
PUFA 
Mean TFA 
B  A  B  A  B  A  B  A  B  A 
Males 
Toddlers   19.3  18.9  14.7  18.3  5.0  3.7  0.9  1.4  0.9  0.9 
Children   24.0  23.4  21.1  28.2  7.7  5.6  1.4  2.4  1.3  1.2 
Teenagers  28.3  27.9  27.9  38.0  10.4  7.4  2.0  3.9  1.6  1.5 
Adults  29.7  29.1  29.2  37.5  11.7  8.2  2.4  3.2  1.8  1.7 
Elderly  30.4  29.7  26.3  31.8  10.6  7.4  2.4  2.8  1.9  1.8 
Females 
Toddlers   18.1  17.7  14.0  18.1  5.1  3.5  0.9  1.6  0.9  0.8 
Children  22.8  22.3  20.8  27.8  7.8  5.5  1.5  2.6  1.3  1.2 
Teenagers  22.9  22.5  23.6  34.1  9.0  6.0  1.8  3.6  1.4  1.3 
Adults  22.4  22.0  21.6  27.6  9.0  6.4  1.9  2.6  1.3  1.3 
Elderly  24.0  23.6  19.9  23.8  8.0  5.9  1.9  2.2  1.4  1.4 
(a):  Consumer group by age: toddlers (1–3 years), children (4–10 years), teenagers (11–18 years), adults (19–64 years) and 
the elderly (≥ 65 years). 
Table 3:   Estimated daily intake (E %) of fatty acid groups before (B) and after (A) the replacement 
of the vegetable oils with the soybean 305423 oil 
Consumer 
group 
(a) 
Mean SFA  Mean MUFA  Mean n-6 PUFA  Mean n-3 
PUFA 
Mean TFA 
B  A  B  A  B  A  B  A  B  A 
Males 
Toddlers   14.7  14.7  11.3  14.6  3.9  3.2  0.7  1.2  0.7  0.7 
Children   13.4  13.5  11.9  16.7  4.4  3.6  0.8  1.5  0.7  0.7 
Teenagers  12.5  12.6  12.5  17.7  4.8  3.8  0.9  1.8  0.7  0.7 
Adults  12.1  12.2  11.9  16.1  4.8  3.9  1.0  1.4  0.7  0.7 
Elderly  13.8  14.0  11.9  15.3  4.8  4.0  1.1  1.4  0.9  0.8 
Females 
Toddlers   14.8  14.8  11.4  15.2  4.1  3.2  0.7  1.4  0.7  0.7 
Children  13.3  13.4  12.2  17.2  4.6  3.7  0.9  1.6  0.7  0.7 
Teenagers  12.4  12.6  12.9  19.4  4.9  3.7  1.0  2.0  0.8  0.7 
Adults  12.1  12.2  11.6  15.7  4.9  4.0  1.0  1.5  0.7  0.7 
Elderly  14.0  14.2  11.7  14.7  4.8  4.0  1.1  1.3  0.8  0.8 
(a):  Consumer group by age: toddlers (1–3 years), children (4–10 years), teenagers (11–18 years), adults (19–64 years) and 
the elderly (≥ 65 years). 
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44 The applicant also considered two other scenarios with lower substitution rates (50 % and 20 %). Scientific opinion on GM soybean 305423 
 
EFSA Journal 2013;11(12):3499  22 
EFSA has not set a dietary reference value for SFA. Several international and national authorities on 
nutrition recommend SFA intakes of < 10 E % (see EFSA NDA Panel, 2010). The baseline SFA 
intake in all population groups (see Table 2) is higher than 10 E %, but does not change through the 
replacement of vegetable oils with soybean 305423 oil. 
As expected, the intake of oleic acid, and consequently that of MUFA, considerably increased in all 
age  groups  when  commercial  vegetable  oils  were  repla ced  by  soybean 305423  oil.  No  dietary 
reference value has been set for MUFA by EFSA  (see EFSA   NDA Panel, 2010).  However, the 
calculated increased intakes of MUFA (16 E % vs. 12 E %) are in the range of those observed for 
adults in EU countries (11–21 E %). 
Linoleic acid (LA) is the main dietary n-6 PUFA in the human diet. EFSA has proposed an adequate 
intake (AI) for LA of 4 E %, based on the lowest estimated mean intakes of the various population 
groups from a number of European countries, where LA deficiency symptoms are not present. This AI 
corresponds to 9 g linoleic acid/day for an energy intake of 2 000 kcal. Replacement of vegetable oil 
with soybean 305423 oil would result in 4 E % for adults and the elderly. Reduction below the AI was 
observed for toddlers, children and teenagers (3.2–3.8 E %). The EFSA GMO Panel is of the opinion 
that this is not a matter of concern, as LA deficiency symptoms have not been observed at intakes 
> 1 E % (EFSA NDA Panel, 2010). As no baseline data for the LA intake at the percentile below the 
mean were available, an estimate on the consequences of the replacement of vegetable oils with the 
soybean 305423 oil for the population sub-groups could not be made. 
Alpha-linolenic acid (ALA) is the main dietary n-3 PUFA. EFSA has proposed an AI for ALA of 
0.5 E %, based on the lowest estimated mean intakes of the various population groups from a number 
of European countries, where ALA deficiency symptoms are not present. The intake of n-3 PUFA, 
predominantly ALA, was found to be between 1.9–2.3 g/day in adult men (0.7–1.2 E %) and 1.5–
1.8 g/day in women (0.7–1.2 E %) in five European countries (EFSA NDA Panel, 2010). Replacement 
of vegetable oils with soybean 305423 oil was calculated to result in an increase of the n-3 PUFA 
consumption for all age groups (see Tables 1 and 2). The Panel notes that the 9,15 isomer of LA 
contributes to the n-3 PUFA values taken for the exposure scenario. However, this isomer cannot be 
converted to ʱ-linolenic acid, because humans lack ∆12 desaturase. As the 9,15 ALA isomer amounts 
to less than 10 % of the total n-3 PUFA, it has little impact on the main outcome. 
TFA  is  considered  undesirable  and,  consequently,  the  intake  should  not  exceed  1 E %,  as  is 
recommended by international and national authorities. The mean TFA consumption of all age groups 
at baseline was below this value and did not appreciably change after replacement of vegetable oils 
with  soybean 305423  oil  (see  Tables  1  and  2).  This  is  also  true  for  high  consumers  (97.5th 
percentile).
45 
5.1.5.2.  Odd chain fatty acids 
The dominant odd chain fatty acids (heptadecanoic (C17:0), heptadecenoic (C17:1) and isomer 1 and 
2 of nonadecenoic acid (C19:1)) sum to 2.7 % in the soybean 305423, compared with about 0.3 % in 
the conventional counterpart. On request of the EFSA GMO Panel, the applicant provided an exposure 
assessment for the odd chain fatty acids. A daily soybean oil consumption per capita of 36 g/day was 
calculated as the mean of 23 European Union (EU) countries based on the FAOSTAT databases as 
well as annual production and trade data (1961–2005) (FAOSTAT, 2005). However, the basis for this 
assessment was analytical values of the refined–bleached–deodorised soybean 305423 oil taken from 
the 2005 field trial. Recalculating using the 2011 data on which the exposure assessment (section 
5.1.4.1)  is  based  indicated  the  average  daily  intake  of  0.9 g  of  odd  chain  fatty  acids  from 
soybean 305423 compared with 0.1 g from its conventional counterpart. 
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Odd chain fatty acids are normal constituents of the human diet (soy products, shortening, margarine, 
tofu, butter, pork, beef and lamb).
46 There appear to be no published studies on the catabolism of these 
odd chain fatty acids in mammals. However, it is thought to be likely that they are metabolised by β-
oxidation,  like  even  chain  fatty  acids.  The  terminal  metabolite  is  expected  to  be  propionyl-CoA 
(instead of acetyl-CoA). Heptadecanoic acid and heptadecenoic acid are also found in human tissues, 
(Shenolikar, 1980; Wendel, 1989; Andersson et al., 2002; Baylin et al., 2002). 
5.1.5.3.  Conclusion on nutritional impact in humans 
Full  replacement  of  vegetable  oils  with  oil  derived  from  soybean 305423  would  not  change 
substantially the average intake of SFA and n-3 PUFA, but would increase MUFA and odd chain fatty 
acids, and decrease n-6 PUFA intake. These changes are small and without impact on health and 
nutrition.  
Other soybean products for human consumption are not expected to differ in their composition, except 
for their fatty acids content. The contribution of fatty acids from  such products to overall human 
exposure would be small and is not expected to affect the conclusion on human health and nutrition.  
5.1.5.4.  Animal nutritional assessment
47 
Presently, only small amounts of full-fat soybeans (1 % of the total soybean feed) are directly fed to 
food-producing animals. The use of soybean oil in animal feed is limited and only small amounts (0.5–
3 %) are added to mixed feed (especially for poultry and pigs) in order to avoid dust, improve the 
quality/stability of pellets and add energy to the diets. Defatted toasted soybean meal represents the 
most common soybean byproduct used in zootechnical animal feed formulations, with around 90 % of 
the defatted soybean meal entering the feed chain in the EU, mainly to poultry, pigs and cattle.
48 
In the animal feeding studies provided by the applicant, diets included mainly toasted defatted soybean 
meals from  soybean 305423, the conventional counterpart (in the laying hen and  pig studies), the 
negative segregant (in the rat and chicken studies) and non-GM commercial varieties. Soybean 305423 
oil (with the expected compositional changes in fatty acids profile) was tested at a low inclusion rate 
(0.5 %) in the chicken study only. Diets were designed to deliver the same nutrition as the concurrent 
control diets and, overall, no significant differences were noted between groups. Furthermore, in the 
food-producing species tested (chickens, laying hens and pigs) performance parameters fell within the 
ranges defined by data from concurrent groups fed diets cont aining commercial  non-GM soybean 
meal varieties (see section 5.1.3). The EFSA GMO Panel is of the opinion that the incorporation of 
feeding stuff derived from soybean 305423 to nutritionally balanced diets has no impact on health and 
performance of the tested species. 
5.1.6.  Post-market monitoring of GM food/feed 
A proposal for a post-market monitoring (PMM) plan needs to be provided by the applicant (EFSA, 
2006b, 2011c). EFSA recommends that the PMM should focus on the collection of consumption data 
for the European population. 
5.2.  Conclusion 
Full  replacement  of  vegetable  oils  with  oil  derived  from  soybean 305423  would  not  change 
substantially the average intake of SFA and n-3 PUFA, but would increase the average intake of 
MUFA and odd chain fatty acids, and decrease n-6 PUFA intake. These changes in average intake are 
small and without impact on health and nutrition. The contribution of fatty acids from soybean 305423 
in other soybean products to overall human exposure would be small and is not expected to affect the 
conclusion on human health and nutrition. 
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The safety assessment identified no concerns regarding the potential toxicity and allergenicity of the 
newly introduced GM-HRA protein. There are no indications that the genetic modification might 
significantly  change  the  overall  allergenicity  of  soybean 305423  when  compared  with  that  of  its 
conventional counterpart. 
Based on the results of studies in chickens for fattening, laying hens, pigs and rats, it is concluded that 
feeding stuffs derived from soybean 305423 are safe and as nutritious as those derived from other non-
GM soybean varieties for all animal species. 
6.  Environmental risk assessment and monitoring plan 
6.1.  Evaluation of relevant scientific data 
Considering the scope of application EFSA-GMO-NL-2007-45, the environmental risk assessment 
(ERA) of soybean 305423 is concerned mainly with ingestion by animals and their manure and faeces 
leading to exposure of the gastrointestinal tract and soil microorganisms to recombinant DNA and 
with accidental release into the environment of viable soybean 305423 grains during transport and 
processing. 
As the scope of the present application excludes cultivation, environmental concerns in the EU related 
to the use of ALS-inhibiting herbicides on soybean 305423 do not apply. 
6.1.1.  Unintended effects on plant fitness due to the genetic modification
49 
Cultivated soybean (Glycine max (L.) Merr.) is a species in the sub-genus Soja of the genus Glycine. 
The species originated from eastern Asia and is a highly domesticated crop (Lu, 2005). The major 
worldwide soybean producers are Argentina, Brazil, China, North Korea, South Korea and the USA. 
In the EU,
50,51 soybean is mainly cultivated in Italy, Romania, France, Hungary, Austria, Slovakia and 
the Czech Republic (Dorokhov  et al., 2004; Krumphuber, 2008). Cultivated soybean seeds rarely 
display  any  dormancy  characteristics,  and  only  under  certain  environmental  conditions  grow  as 
volunteers in the year following cultivation. If volunteers occur, they do not compete well with the 
succeeding crop, and can easily be controlled mechanically or chemically (OECD, 2000). In soybean 
fields, seeds usually do not survive during the winter owing to predation, rotting and germination 
resulting in death, or owing to management practices prior to planting the subsequent crop (Owen, 
2005). 
For  the  assessment  of potential  impacts  on  the  environment  in case  of  accidental  release of  GM 
soybean  grains  during  transport  and  processing,  the  EFSA  GMO  Panel  mainly  considered  the 
comprehensive 2011 dataset in the USA and Canada (for further details, see section 4.1.2). Laboratory 
tests and field studies at several locations in the USA (nine locations) and Canada (one location) in 
2011  have  been  carried  out  to  assess  the  phenotypic  and  agronomic  characteristics  as  well  as 
ecological interactions of GM soybean 305423 in comparison with an appropriate comparator and 
several  non-GM  soybean  reference  varieties.  Considering  the  scope  of  the  application,  special 
attention is paid to those agronomic characteristics (e.g. early and final plant population, seedling 
vigour, and yield) which may affect the survival, establishment and fitness of the GM soybean grains 
which could be accidentally released into the environment.  
Some  statistically  significant  differences  (e.g.  for  early  and  final  plant  population,  plant  height, 
shattering, seedling vigour and yield) were observed in the across-location statistical analysis of the 
2011 dataset in the USA and Canada. Both the soybean 305423 samples sprayed with the intended 
herbicide  and  the  samples  sprayed  with  conventional  herbicides  had  lower  early  and  final  stand 
counts, seedling vigour and yield than their comparators. The equivalence test indicated that all the 
analysed  characteristics  fell  within  the  equivalence  limits  established  from  the  non-GM  soybean 
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reference  varieties,  except  for  lodging  when  soybean 305423  was  sprayed  with  conventional 
herbicides (see section 4.1.3). The observed differences are not considered environmentally relevant in 
the context of the scope of this application, as they suggest a lower fitness of soybean 305423. The 
EFSA GMO Panel considers that the differences observed are unlikely to affect the overall fitness, 
invasiveness or weediness of the GM soybean, except under conditions of application of the intended 
herbicide. 
The herbicide tolerance trait can be regarded as providing only a potential agronomic and selective 
advantage to this GM soybean plant where and when ALS-inhibiting herbicides are applied. However, 
survival of soybean plants outside cultivation where ALS-inhibiting herbicides are applied is mainly 
limited by a combination of low competitiveness, absence of a dormancy phase and susceptibility to 
plant  pathogens  and  cold  climatic  conditions.  As  these  general  characteristics  are  unchanged  in 
soybean 305423, herbicide tolerance is not likely to provide a selective advantage outside cultivation. 
Even if ALS-inhibiting herbicides are applied to these plants, it will not change their ability to survive 
over  seasons.  Therefore,  it  is  considered  very  unlikel y  that  soybean 305423  will  differ  from 
conventional soybean varieties in its ability to survive until subsequent seasons or to establish feral 
populations under European environmental conditions. 
Therefore, from the data presented in the application, there is no indication of an increased persistence 
and invasiveness  potential of  soybean 305423 compared with conventional soybean and it can be 
considered that soybean 305423 has no altered survival, multiplication or dissemination characteristics 
compared with its conventional counterpart, except under application of ALS-inhibiting herbicides. 
In addition to the data presented by the applicant, the EFSA GMO Panel is not aware of any scientific 
report of increased spread and establishment of existing GM soybeans and any change in survival 
capacity, including overwintering (Dorokhov  et al.,  2004; Owen, 2005; Bagavathiannan and Van 
Acker, 2008; Lee et al., 2008). 
Therefore, the EFSA GMO Panel is of the opinion that the likelihood of unintended environmental 
effects of soybean 305423 in Europe will not be different to that of conventional soybean varieties. 
6.1.2.  Potential for gene transfer
52 
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic material, 
either through horizontal gene transfer of DNA, or vertical gene flow via seed dispersal and cross-
pollination. 
6.1.2.1.  Plant-to-bacteria gene transfer 
Genomic DNA is a component of many food and feed products derived from soybean. It is well 
documented that DNA present in food and feed becomes substantially degraded during processing and 
digestion in the human or animal gastrointestinal tract. However, a low level of exposure of fragments 
of ingested DNA, including the recombinant fraction of such DNA, to bacteria in the digestive tract of 
humans, domesticated animals and other animals feeding on the GM soybean is expected. 
Current scientific knowledge of recombination processes in bacteria indicates that horizontal transfer 
of non-mobile, chromosomally located DNA fragments between unrelated organisms (such as plants 
to bacteria) is not expected to occur at detectable frequencies under natural conditions (see EFSA, 
2009, for further details). 
A  successful  horizontal  transfer  would  require  stable  insertion  of  the  transgene  sequences  into  a 
bacterial  genome  and  a  selective  advantage  conferred  to  the  transformed  host.  The  only  known 
mechanism  that  facilitates  horizontal  transfer  of  non-mobile,  chromosomal  DNA  fragments  into 
bacterial  genomes  is  homologous  recombination. This  requires the  presence of  stretches  of  DNA 
sequences that are similar in the recombining DNA molecules and, in addition to substitutive gene 
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replacement, facilitates the insertion of non-homologous DNA sequences if their flanking regions 
share sequence similarity with bacterial sequences in the recipient. 
Soybean 305423 contains a gm-fad2-1 gene fragment leading to a decreased level of the fatty acid 
desaturase and the gm-hra gene which confers tolerance to ALS-inhibiting herbicides. Both gm-fad2-1 
and  gm-hra  genes,  as  well  as  their  regulatory  sequences,  are  of  soybean  origin.  Furthermore, 
soybean 305423  was  obtained  by  particle  bombardment.  The  analyses  of  the  recombinant  DNA 
revealed  the  presence  of  a  495-bp-long  sequence  originating  from  the  plasmid  PHP19340  or 
PHP17752, which must be of bacterial origin. This fragment, however, is considered to be a non-
functional fragment; thus, it is not a regulatory element and it does not encode a functional protein. 
Therefore, in the very unlikely but theoretically possible case of transfer of this gene facilitated by 
homologous recombination or also by illegitimate recombination to natural plasmids, no trait would be 
conferred.  
Owing to the plant origin of all genetic elements of the inserts encoding for functional genes in 
soybean 305423, no increased likelihood for homologous recombination compared to DNA from non-
GM soybean were identified. Furthermore, no risk was identified for the unlikely but theoretically 
possible transfer of the non-functional DNA fragment of bacterial origin to plasmids as they may 
occur in environmental bacteria. 
6.1.2.2.  Plant-to-plant gene transfer 
Considering the scope of this application and physical characteristics of soybean seeds, a possible 
pathway of gene dispersal is from grain spillage and pollen of occasional feral GM soybean plants 
originating from accidental grain spillage during transport and/or processing. 
The genus Glycine is divided into two distinct sub-genera: Glycine and Soja. Soybean belongs to the 
sub-genus Soja. The sub-genus Glycine contains 16 perennial wild species, whereas the cultivated 
soybean, Glycine max, and its wild and semi-wild annual relatives, Glycine soja and Glycine gracilis, 
are classified in the sub-genus Soja (OECD, 2000). Owing to the low level of genomic similarity 
among species of the genus Glycine, Glycine max can only cross with other members of the Glycine 
sub-genus Soja (Hymowitz et al., 1998; Lu, 2005). Hence, the three species of the subgenus Soja are 
capable of cross-pollination and the hybrid seed that is produced can germinate normally and produce 
plants with fertile pollen and seed (Abe et al., 1999; Nakayama and Yamaguchi, 2002). However, as 
G. soja and G. gracilis are indigenous to Australia, China, Japan, Korea, the Philippines, the far 
eastern region of Russia, the South Pacific and Taiwan, and as they have not been reported in other 
parts of the world where the cultivated soybean is grown (Dorokhov et al., 2004; Lu, 2005), the plant-
to-plant gene transfer from soybean in the EU is restricted to cultivated soybean. 
Soybean  (Glycine  max)  is  an  annual,  almost  completely  self-pollinating  crop  in  the  field,  with  a 
percentage of cross-pollination usually lower than 1 % (Weber and Hanson, 1961; Caviness, 1966; 
Ray et al., 2003; Lu, 2005; Yoshimura et al., 2006; Abud et al., 2007). Soybean pollen dispersal is 
limited because the anthers mature in the bud and directly pollinate the stigma of the same flower 
(OECD,  2000).  However,  cross-pollination rates as  high  as  6.3 % have  been  reported  for  closely 
spaced  plants (Ray  et  al.,  2003),  suggesting  the  potential  for  some  within-crop  gene flow. These 
results indicate that natural cross-pollination rates can fluctuate significantly among different soybean 
varieties under particular environmental conditions, such as favourable climate for pollination and 
abundance  of  pollinators  (Gumisiriza  and  Rubaihayo,  1978;  Kikuchi  et  al.,  1993;  Ahrent  and 
Caviness, 1994; Ray et al., 2003; Lu, 2005). 
Plant-to-plant gene transfer could therefore occur under the following scenarios: imports of viable 
soybean 305423  grains  (while  most  soybean 305423  grains  will  be  processed  in  countries  of 
production), processing outside of importing ports, transportation in regions of soybean production in 
Europe, spillage of GM grains during transport, germination and development of spilled grains within 
soybean fields or in very close vicinity of cultivated soybean fields, overlap of flowering periods and 
environmental  conditions  favouring  cross-pollination.  The  overall  likelihood  of  cross-pollination Scientific opinion on GM soybean 305423 
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between GM soybean plants and cultivated soybean is therefore extremely low. Apart from seed 
production areas, GM plants and plants derived from out-crossing with this GM soybean will not 
persist overtime. Dispersal of soybean seeds by animals is not expected owing to the characteristics of 
the  seed,  but  accidental  release  into  the  environment  of  grains  may  occur  during  transport  and 
processing for food, feed and industrial uses. However, cultivated soybean seeds rarely display any 
dormancy characteristics and only under certain environmental conditions grow as volunteers in the 
year following cultivation. If volunteers occur, they do not compete well with the succeeding crop, and 
can easily be controlled mechanically or chemically (OECD, 2000). Even in soybean fields,  seeds 
usually do not survive during the winter owing to predation, rotting, germination resulting in death or 
management practices prior to planting the subsequent crop (Owen, 2005). 
The EFSA GMO Panel takes into account the fact that this application does not include cultivation of 
the soybean within the EU so that the likelihood of cross-pollination between cultivated soybean and 
occasional soybean plants resulting from seed spillage is considered extremely low. However, in 
countries cultivating this GM soybean and producing seed for export, there is a potential for admixture 
in seed production and thus the introduction of GM seeds through this route. 
In conclusion, as there are no significant changes of overall fitness, invasiveness or weediness of 
soybean 305423 with respect to conventional soybean, the EFSA GMO Panel is of the opinion that the 
likelihood  of  unintended  environmental  effects  as  a  consequence  of  spread  of  genes  from 
soybean 305423 in Europe will not differ from that of conventional soybean varieties. 
6.1.3.  Interactions of the GM plant with target organisms
53 
Considering the scope of this application, excluding cultivation, and the absence of target organisms, 
potential interactions of the GM plant with target organisms were not considered an issue by the EFSA 
GMO Panel. 
6.1.4.  Interactions of the GM plant with non-target organisms
54 
Considering the scope of this application, excluding cultivation, and the low level of exposure to the 
environment, potential interactions of soybean 305423 with non-target organisms were not considered 
an issue by the EFSA GMO Panel. 
6.1.5.  Interactions with the abiotic environment and biogeochemical cycles
55 
Considering the scope of this application, excluding cultivation, and the low level of exposure to the 
environment, potential interactions of the GM plant with the abiotic environment and biogeochemical 
cycles were not considered an issue by the EFSA GMO Panel. 
6.2.  Post-market environmental monitoring
56 
The objectives of a post-market environmental monitoring (PMEM) plan according to Annex VII of 
Directive 2001/18/EC are (1) to confirm that any assumption regarding the occurrence and impact of 
potential adverse effects of the GMO, or its use, in the environmental risk assessment are correct and 
(2) to identify the occurrence of adverse effects of the GMO, or its use, on human health or the 
environment which were not anticipated in the ERA. 
Monitoring is related to risk management and thus a final adoption of the PMEM plan falls outside the 
mandate of EFSA. However, the EFSA GMO Panel gives its opinion on the scientific content of the 
monitoring plan provided by the applicant (EFSA, 2011). The potential exposure to the environment 
of soybean 305423 would be through ingestion by animals and their manure and faeces leading to 
exposure of the gastrointestinal tract and soil microbial populations to recombinant DNA and through 
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accidental release into the environment of GM soybean grains during transport and/or processing. The 
PMEM  plan  provided  by  the  applicant  is  in  line  with  the  scope  of  the  application.  As  the 
environmental  risk  assessment  did  not  cover  cultivation  and  identified  no  potential  adverse 
environmental effects, no case-specific monitoring is necessary. 
The PMEM plan proposed by the applicant includes: (1) the description of an appro ach involving 
operators (federations involved in soybean import and processing) reporting to the applicant, via a 
centralised  system,  any  observed  adverse  effect(s)  of  GM  organisms  on  human  health  and  the 
environment, (2) a coordinating system established  by EuropaBio for the collection of information 
recorded by the various operators (Lecoq et al., 2007; Windels et al., 2008) and (3) the use of networks 
of existing surveillance systems. The applicant proposes to submit a PMEM report on an annual basis 
and a final report at the end of the consent. 
The EFSA GMO Panel is of the opinion that the PMEM plan proposed by the applicant is in line with 
the scope of the application as the ERA of soybean 305423 did not cover cultivation and identified no 
potential  adverse  environmental  effects  (EFSA,  2011).  In  addition ,  the  EFSA  GMO  Panel 
acknowledges the approach proposed by the applicant to put in place appropriate management systems 
to restrict environmental exposure in case of accidental release of viable grains of  soybean 305423. 
The EFSA GMO Panel agrees with the reporting intervals proposed by the applicant in the PMEM 
plan. 
6.3.  Conclusion 
Considering  the  scope  of  application  EFSA-GMO-NL-2007-45,  the  ERA  of  soybean 305423  is 
concerned with indirect exposure, mainly through ingestion by animals and their manure and faeces 
leading to exposure of the gastrointestinal tract and soil bacteria to recombinant DNA and through the 
accidental release into the environment of viable soybean 305423 grains (e.g. during transport and/or 
processing). 
In the case of accidental release into the environment of viable grains of soybean 305423, there are no 
indications of an increased likelihood of establishment and spread of feral soybean 305423 plants, 
except  in  the  presence  of  ALS-inhibiting  herbicides.  Considering  the  scope  of  the  application, 
potential interactions of soybean 305423 with the biotic and abiotic environment were not considered 
to be an issue by the EFSA GMO Panel. Furthermore, the EFSA GMO Panel is of the opinion that the 
unlikely  but  theoretically  possible  transfer  of  the  recombinant  gene  from  soybean 305423  to 
environmental bacteria does not raise concern owing to the lack of a selective advantage in the context 
of the scope of the application. 
The  PMEM  plan  provided  by  the  applicant  is  in  line  with  the  scope  of  the  application  and  the 
Guidance document of the EFSA GMO Panel on PMEM of GM plants (EFSA, 2011). In addition the 
EFSA GMO Panel acknowledges the approach proposed by the applicant to put in place appropriate 
management systems to restrict environmental exposure in case of accidental release of viable grains 
of  soybean 305423.  The  EFSA  GMO  Panel  agrees  with  the  reporting  intervals  proposed  by  the 
applicant in its PMEM plan. 
OVERALL CONCLUSIONS AND RECOMMENDATIONS 
The EFSA GMO Panel was requested to carry out a scientific assessment of soybean 305423 for food 
and feed uses, import and processing in accordance with Regulation (EC) No 1829/2003. 
The  EFSA  GMO  Panel  is  of  the  opinion  that  the  molecular  characterisation  data  provided  for 
soybean 305423 are sufficient to conclude on this part of the risk assessment evaluation. The results of 
the bioinformatic analyses of the inserted DNA and the flanking regions do not raise safety issues. The 
levels  of  Glycine  max  herbicide-resistant  ALS  (GM-HRA)  protein  in  soybean 305423  have  been 
sufficiently analysed in various tissues. One plant out of the 1 100 tested individuals had undergone 
recombination  and,  as  a  result,  had  lost  the  entire  gm-hra  cassette  and  portions  of  the  promoter Scientific opinion on GM soybean 305423 
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elements  flanking  the  cassette.  However,  the  EFSA  GMO  Panel  is  of  the  opinion  that  this 
recombination, leading to loss of the trait, raises no safety issues. The stability of the inserted DNA 
was  confirmed  over  several  generations.  The  EFSA  GMO  Panel  considers  that  the  molecular 
characterisation does not indicate a safety issue. 
The EFSA GMO Panel compared the compositional, agronomic and phenotypic characteristics of 
soybean 305423,  with  its  conventional  counterpart  and  non-GM  reference  soybean  varieties  and 
assessed  all  statistically  significant  differences  between  soybean 305423  and  its  conventional 
counterpart, for which equivalence with the non-GM reference varieties could not be established. The 
EFSA  GMO  Panel  concludes  that  the  composition  of  soybean 305423  differs  from  that  of  the 
conventional counterpart and that of non-GM reference varieties in its fatty acid profile, the newly 
expressed protein  max  herbicide-resistant  ALS  (GM-HRA),  consistently  with the  objective  of  the 
modification as well as with the expression of the ALS enzyme of soybean 305423; differences in the 
minerals  zinc  and  calcium  and  the  isoflavone  glycitin  were  also  noted,  and  for  these  no  further 
assessment was deemed necessary owing to their well-known biochemical roles and to the magnitude 
of the reported levels. The EFSA GMO Panel also concludes that no differences were identified in the 
agronomic and phenotypic characteristics that would require further assessment with regard to safety.  
Full  replacement  of  vegetable  oils  with  oil  derived  from  soybean 305423  would  not  change 
substantially the average intake of SFA and n-3 PUFA, but would increase the average intake of 
MUFA and odd chain fatty acids, and decrease n-6 PUFA intake. These changes in the average intake 
are  small  and  without  impact  on  health  and  nutrition.  The  contribution  of  fatty  acids  from 
soybean 305423 in other soybean products to overall human exposure would be small and  is not 
expected to affect the conclusion on human health and nutrition. 
The safety assessment identified no concerns regarding the potential toxicity and allergenicity of the 
newly introduced GM-HRA protein. There are no indications that the genetic modification might 
significantly  change  the  overall  allergenicity  of  soybean 305423  when  compared  with  that  of  its 
conventional counterpart. 
Based on the results of studies in chickens for fattening, laying hens, pigs and rats, it is concluded that 
feeding stuffs derived from soybean 305423 are safe and as nutritious as those derived from other non-
GM soybean varieties for all animal species. 
Considering the intended altered soybean 305423 nutritional composition, a proposal for a post-market 
monitoring  (PMM)  plan  needs  to  be  provided  by  the  applicant  (EFSA,  2006b,  2011c).  EFSA 
recommends that the PMM should focus on the collection of consumption data for the European 
population. 
The scope of application EFSA-GMO-NL-2007-45 is for food and feed uses, import and processing 
and  does  not include cultivation. Therefore,  there is  no  requirement  for scientific  information  on 
possible environmental effects associated with the cultivation of soybean 305423 in Europe. There are 
no indications of an increased likelihood of establishment and spread of feral GM soybean plants in 
the case of accidental release into the environment of viable soybean 305423 grains during transport 
and  processing  for  food  and  feed  uses,  except  in  the  presence  of  ALS-inhibiting  herbicides. 
Considering the scope of this application, potential biotic and abiotic interactions of soybean 305423 
were not considered to be an issue by the EFSA GMO Panel. The unlikely but theoretically possible 
transfer of the recombinant gene from soybean 305423 to environmental bacteria does not raise any 
safety concerns because no selective advantage will be conferred to the recipients. The scope of the 
post-market environmental monitoring plan provided by the applicant is in line with the scope of the 
application. Furthermore, the EFSA GMO Panel agrees with the reporting intervals proposed by the 
applicant in the post-market environmental monitoring plan. 
In conclusion, the EFSA GMO Panel considers that the information available for soybean 305423 
addresses the scientific issues indicated by the Guidance document of the EFSA GMO Panel and the Scientific opinion on GM soybean 305423 
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scientific  comments  raised  by  the  Member  States,  and  that  soybean 305423  is  as  safe  as  its 
conventional counterpart and is unlikely to have adverse effects on human and animal health and the 
environment in the context of the scope of this application. 
Considering the altered composition and nutritional values of soybean 305423, the EFSA GMO Panel 
considered a specific labelling proposal provided by the applicant in accordance with Articles 13(2)(a) 
and 25(2)(c) of Regulation (EC) No 1829/2003. The applicant proposed that food and feed products 
within the scope of the application should be labelled as ―genetically modified soybean with altered 
fatty acid profile‖. The GMO Panel is of the opinion that the compositional data (see section 4.1.3 
above) show that the fatty acid composition of seeds of soybean 305423 and derived oil has indeed 
been changed in relation to the conventional counterpart. Scientific opinion on GM soybean 305423 
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DOCUMENTATION PROVIDED TO EFSA 
1.  Letter from the Competent Authority of the Netherlands, received 18 June 2007, concerning a 
request  for  placing  on  the  market  of  soybean 305423  in  accordance  with  Regulation  (EC) 
No 1829/2003. 
2.  Acknowledgement letter, dated 22 June 2007, from EFSA to the Competent Authority of the 
Netherlands. 
3.  Letter from EFSA to applicant, dated 28 September 2007, requesting additional information under 
completeness check. 
4.  Letter from applicant to EFSA, received 12 October 2007, providing additional information under 
completeness check. 
5.  Letter from EFSA to applicant, dated 22 October 2007, delivering the ―Statement of Validity‖ for 
application  EFSA-GMO-NL-2007-45,  soybean 305423  submitted  by  Pioneer  under  Regulation 
(EC) No 1829/2003. 
6.  Letter from EFSA to applicant, dated 20 December 2007, requesting additional information and 
stopping the clock. 
7.  Letter from applicant to EFSA, received 12 February 2007, providing additional information. 
8.  Letter from EFSA to applicant, dated 28 February 2008, requesting additional information and 
maintaining the clock stopped. 
9.  Letter from applicant to EFSA, received 28 April 2008, providing additional information. 
10. Letter  from  EFSA  to  applicant,  dated  22  May  2008,  requesting  additional  information  and 
maintaining the clock stopped. 
11. Letter from applicant to EFSA, received 4 July 2008, providing additional information. 
12. Letter from  EFSA  to  applicant,  dated  13  August  2008,  requesting  additional information  and 
maintaining the clock stopped. 
13. Letter from applicant to EFSA, received 24 November 2008, providing additional information. 
14. Letter from EFSA to applicant, dated 11 February 2009, requesting additional information and 
maintaining the clock stopped. 
15. Letter from applicant to EFSA, received 19 March 2009, providing additional information. 
16. Letter from applicant to EFSA, received 6 October 2009, providing additional information. 
17. Letter  from  EFSA  to  applicant,  dated  8  January  2010,  requesting  additional  information  and 
maintaining the clock stopped. 
18. Letter from applicant to EFSA, received 9 February 2010, providing additional information. 
19. Letter  from  EFSA  to  applicant,  dated  27  April  2010,  requesting  additional  information  and 
maintaining the clock stopped. 
20. Letter from applicant to EFSA, received 6 June 2010, providing additional information. 
21. Letter  from  EFSA  to  applicant,  dated  5  August  2010,  requesting  additional  information  and 
maintaining the clock stopped. Scientific opinion on GM soybean 305423 
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22. Letter from applicant to EFSA, received 21 September 2010, providing additional information. 
23. Letter from EFSA to applicant, dated 21 October 2010, requesting additional information and 
maintaining the clock stopped. 
24. Letter  from  applicant  to  EFSA,  received  18  November  2010,  requesting  clarifications  on  the 
additional information requested by EFSA. 
25. Letter from EFSA to applicant, dated 22 December 2010, providing clarifications. 
26. Letter from applicant to EFSA, received 9 February 2011, providing the additional information 
requested. 
27. Letter from EFSA to applicant, dated 17 May 2011, re-starting the clock. 
28. Letter from applicant to EFSA, received 14 July 2011, providing clarifications requested by the 
EC. 
29. Letter from applicant to EFSA, received 28 November 2011, requesting clarifications to EFSA. 
30. Letter from applicant to EFSA, received 3 January 2012, requesting clarifications to EFSA. 
31. Letter from EFSA to applicant, dated 12 January 2012, providing clarifications. 
32. Letter from applicant to EFSA, received 17 January 2012, providing additional information. 
33. Letter from applicant to EFSA, received 5 March 2012, providing additional information. 
34. Letter  from  EFSA  to  applicant,  dated  30  May  2012,  requesting  additional  information  and 
maintaining the clock stopped. 
35. Letter from applicant to EFSA, received 5 June 2012, providing additional information. 
36. Letter from EFSA to applicant, dated 19 September 2012, requesting additional information and 
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